Track market-moving stories before they get noisy

Taiwan Semiconductor Manufacturing (TSM +0.23%) has been making huge investments to diversify its production base away from its home island of Taiwan. During its Q2 announcements, Taiwan declared it would invest another $100 billion in its Arizona production facilities, bringing its total to $265 billion. That's a huge move by TSMC, and I think it solidifies the stock as a buy.

If you've got $1,000 sitting around, I can think of few better stocks to pick right now than Taiwan Semiconductor.

Image source: Taiwan Semiconductor Manufacturing Company.

Domestic chip production reduces the risk of disruption One of the biggest fears investors have historically had with Taiwan Semiconductor is its location just off mainland China. The relationship between Taiwan and China is complex, and rumors of military activity have swirled for decades. Any military action would sink TSMC's stock, as production would be disrupted.

However, that military action also may plunge the world into a war, which would wreck all forms of investing (outside of defense and staples stocks). But with TSMC moving more and more production to the U.S., the risk of a single point of failure is decreasing. Obviously, TSMC's stock would likely plummet, but the business wouldn't be as disrupted as it once was.

Today's Change

(

0.23

%) $

0.94

Current Price

$

404.25

Another task the Arizona investment accomplishes is increasing domestic chip production in general. Intel used to be the primary chip foundry business in the U.S. It has lost a lot of clients to TSMC due to its superior technologies and production capabilities. With a push to increase domestic chip production, TSMC either needed to onshore some of its capabilities or deal with Intel being boosted by the U.S. government, making it hard to compete with.

Lastly, Taiwan Semiconductor wouldn't be making these investments if there weren't a demand for increased chip production. During TSMC's Q2 conference call, CEO C.C. Wei stated he believes that AI chip demand will stay strong through at least 2029 to 2030, and that it could last longer due to a new industry being created. If there's enough demand to warrant a $100 billion investment for production facilities, I think investors can stay bullish on the AI trend in general.

With Taiwan Semiconductor being a chip fabricator and benefiting from increased AI spending in general, it's a neutral party that's primed to thrive over the next few years.

TSM PE Ratio (Forward) data by YCharts

At 23.5 times forward earnings, it's also a reasonably priced stock that looks primed to head higher as AI demand reaches new levels.

Keithen Drury has positions in Taiwan Semiconductor Manufacturing. The Motley Fool has positions in and recommends Intel and Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy.

© VideoFlow / Shutterstock.com

Cisco Systems (NASDAQ:CSCO | CSCO Price Prediction) has become one of 2026’s surprising mega-cap winners, riding an AI infrastructure order book that expands each quarter. With shares up 52.76% year to date, the question is whether the rally has room left.

Our 24/7 Wall St. price target for Cisco is $135.69, implying 16.98% upside from the current price of $115.99. Our recommendation is buy, with a 90% confidence level. Cisco executes on the AI opportunity while trading at a materially lower multiple than its highest-flying networking peer.

Metric Value Current Price $115.99 24/7 Wall St. Price Target $135.69 Upside 16.98% Recommendation BUY Confidence Level 90% How a Sleepy Networking Giant Doubled in a Year Cisco is up 73.88% over the past year and up 1.59% in the last week, though shares slipped 0.51% over the past month. The stock sits just below its 52-week high of $129.88, well off the $64.42 low. Q3 FY26 revenue hit $15.84 billion, up 12% YoY, non-GAAP EPS of $1.06 beat consensus, and net income jumped 35.41%.

The driver is AI infrastructure. Management raised FY26 AI order guidance to $9 billion from $5 billion and AI revenue to $4 billion from $3 billion. Total product orders grew 35% YoY, with data center switching orders up over 40%.

The Case for $141 and Higher Bulls see a durable multi-year cycle. Chuck Robbins told analysts, “Cisco delivered record quarterly revenue in Q3 and we saw very strong, broad-based demand for our products, demonstrating the relevance of our technology for connecting and securing AI.”

Silicon One design wins compound, Acacia optics delivered over $1 billion in Q3 orders, and preliminary FY27 guidance calls for at least $6 billion in AI hyperscale revenue.

Our bull case points to $141.49, or 21.98% upside. Analysts including a $130.23 consensus, with 17 Buy ratings, support re-rating toward peer multiples.

What Could Go Wrong Non-GAAP gross margin compressed 260 basis points YoY to 66% in Q3 on hardware mix shift and memory costs. Services revenue slipped 1%, and hyperscaler AI order timing is “nonlinear”. Insider activity skewed toward selling, and the trailing P/E of 38 leaves little margin for error.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Cisco Systems didn't make the cut. Grab the names FREE today.

Our bear case implies $112.38, or 3.12% downside. Bulls counter that margin compression reflects a deliberate mix shift toward high-volume AI hardware where dollar profit expands, and that the $1 billion restructuring charge represents reinvestment for future growth.

How Cisco Compares to Arista and HPE Arista Networks (NYSE:ANET) is the premium comp. Arista trades at a forward P/E of 47 with 35.1% YoY revenue growth and 42.7% operating margins. Cisco’s forward P/E of 24 looks cheap by comparison, even accounting for slower growth. A modest re-rating toward Arista could make our $135.69 target conservative.

Hewlett Packard Enterprise (NYSE:HPE) is the value counterpoint. HPE trades at a forward P/E of 12 with 40% revenue growth post-Juniper, but operating margins are just 8.7%. Cisco’s 25% operating margin and 25.2% ROE justify the premium.

Company Forward P/E Operating Margin Cisco 24 25% Arista 47 42.7% HPE 12 8.7% Cisco Price Prediction 2026-2030 The 24/7 Wall St. price target of $135.69 with a buy rating and 90% confidence reflects a company that moved from perpetual show- me story to legitimate AI infrastructure leader. The tipping factor is the FY26 AI order ramp to $9 billion, backed by real Silicon One and Acacia design wins.

The setup looks constructive if Q4 revenue lands within the $16.7B to $16.9B guidance range and hyperscaler orders continue the trajectory. The thesis weakens if gross margin compression accelerates below 65% or hyperscaler orders slip below $3 billion in Q4.

Looking further out, here is where our model projects Cisco could trade, assuming FY27 AI hyperscale revenue lands at or above the $6 billion preliminary guide and non-AI growth stays in the 4% to 6% band.

Year 24/7 Wall St. Price Target 2026 $135.69 2027 $150.00 2028 $165.00 2029 $178.00 2030 $190.77 These projections assume Cisco executes on its silicon and optics roadmap. Meaningful upside or downside could come from Silicon One share gains at additional hyperscalers or a hyperscaler capex reset.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Cisco Systems didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme (PBS) for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).[1],[2] In the pivotal Phase 3 inMIND clinical trial, patients with R/R FL receiving the Minjuvi combination regimen experienced a significant improvement in progression-free survival, with a 57% reduction in the risk of disease progression, relapse or death, compared with placebo plus lenalidomide and rituximab.[3] Follicular lymphoma is the second most common non-Hodgkin lymphoma (NHL), with over 10,000 Australians living with the disease and approximately 1,500 Australians diagnosed each year.[4],[5] , /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the listing of Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, on the Pharmaceutical Benefits Scheme (PBS) for the treatment of Australian adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).[1] This milestone follows the Australian registration of Minjuvi for R/R FL by the Therapeutic Goods Administration (TGA) in April 2026, via the Project Orbis process.[6]

The PBS listing of Minjuvi marks the availability of the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen funded in Australia for this group of patients.[1],[2] Effective 1 August 2026, eligible patients with FL who have experienced relapses or disease progression on existing therapies will now have equitable access to a new treatment option for this difficult-to-treat condition.[1]

"As the first new therapy to be reimbursed on the PBS for R/R FL in nine years, we are extremely proud to have partnered with Incyte to bring Minjuvi to Australia," said Carlo Montagner, ST Chief Executive Officer. "After securing TGA registration for Minjuvi in R/R FL earlier this year, we have been focused on expediting PBS listing to ensure eligible Australian patients could have subsidised access to a new treatment option that may help lower the risk of disease progression, relapse or death, without delay."

ST entered into an exclusive distribution agreement with Incyte (NASDAQ:INCY) in 2021 to commercialise Minjuvi in Australia, New Zealand and Singapore.

Minjuvi is a CD19 targeting immunotherapy that works within a patient's immune system to help find and eliminate malignant B-cells.[7] In combination with rituximab and lenalidomide, Minjuvi delivers a complementary immune-mediated approach that helps control disease progression and supports improved long-term outcomes for patients with follicular lymphoma.[7]

The PBS reimbursement underscores the growing recognition of innovative immunotherapy-based treatment strategies in follicular lymphoma and reinforces ST's commitment to improving access to life-changing therapies for patients across the Asia-Pacific region.

"While follicular lymphoma can be a slow-growing disease that usually responds well to the first treatment, most patients are not cured. Many patients experience frequent relapses and require multiple therapies over their lifetime, which become progressively less effective, especially for those whose disease comes back soon after initial chemotherapy treatment," said Associate Professor Philip Thompson, Clinical Haematologist at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital in Melbourne. "Today's PBS listing announcement is welcome news for the Australian clinical and patient community, providing us with a new, chemotherapy-free immunotherapy treatment for R/R FL."

Minjuvi is administered via intravenous (IV) infusion in a clinic or hospital setting.[7] Patients with R/R FL receive up to 12 treatment cycles of Minjuvi, along with oral lenalidomide capsules, while rituximab is delivered intravenously for the first five cycles.[7]

"Knowing that a chemotherapy-free immunotherapy is now funded by the PBS is an important development for the follicular lymphoma community," said Sharon Winton, Chief Executive Officer of Lymphoma Australia. "As patients manage the challenges of recurring disease, this new treatment milestone offers a valuable option that is deeply meaningful to them and their families."

The PBS listing of Minjuvi for R/R FL means these patients will now have equitable access to a new targeted immunotherapy combination treatment when they need it. It is important that patients with R/R FL speak with their doctor to understand the most suitable treatment option available for them.

For further details on Minjuvi, contact your healthcare professional and please refer to the approved Australian Consumer Medicine Information or Product Information available from the TGA website.

PBS Information:

This medicine is listed on the Pharmaceutical Benefits Scheme (PBS) — AUTHORITY REQUIRED. Refer to the PBS Schedule www.pbs.gov.au for full authority information.

Important Safety Information on Minjuvi[7]

Minjuvi should be administered to patients with an active infection only if the infection is treated appropriately and well controlled. Patients with a history of recurring or chronic infections may be at increased risk of infection and should be monitored appropriately. Patients should be advised to contact their healthcare professionals if fever or other evidence of potential infection, such as chills, cough or pain on urination, develops.

Treatment with Minjuvi in combination with lenalidomide and/or rituximab should not be initiated in female patients unless pregnancy has been excluded. In the inMIND study, the most common adverse reactions were infections (68%), including viral infections (41%) and bacterial infections (27%); neutropenia (57%), rash (36.4%), asthenia (34.9%), pyrexia (19%), thrombocytopenia (17%), anaemia (17%), infusion related reaction (15.9%), pruritus (15.6%), and headache (10.4%). The most common serious adverse reactions were infections (26%), including viral infections (13%) and bacterial infections (6%), febrile neutropenia (2.8%), and pyrexia (1.8%).

Treatment with tafasitamab can cause serious or severe myelosuppression including neutropenia, thrombocytopenia, and anaemia. Complete blood counts should be monitored throughout treatment and prior to administration of each treatment cycle.

Ends.

About Minjuvi® (tafasitamab)

Minjuvi® (tafasitamab) is a humanised Fc-modified cytolytic CD19-targeting monoclonal antibody. Minjuvi incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).[7] Incyte licenses exclusive worldwide rights to develop and commercialise Minjuvi from Xencor, Inc. 

In the U.S., Monjuvi® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). Additionally, Monjuvi received accelerated approval in the United States in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for ASCT. 

Monjuvi is not indicated and is not recommended for the treatment of patients with relapsed or refractory marginal zone lymphoma outside of controlled clinical trials. 

In Europe, Minjuvi® (tafasitamab) received conditional Marketing Authorisation from the European Medicines Agency in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT. In addition, in December 2025, the EMA approved Minjuvi, in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory FL (Grade 1-3a) after at least one line of systemic therapy. 

In Japan, Minjuvi is approved in combination with lenalidomide for the treatment of adults with relapsed or refractory DLBCL. Minjuvi is also approved in combination with rituximab and lenalidomide for adult patients with relapsed or refractory FL (2L+ FL). 

In Australia, Minjuvi® (tafasitamab) is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).[7]

▼ This medicine is included in the TGA Black Triangle Scheme. Please report suspected adverse events to the TGA.[7]

XmAb® is a registered trademark of Xencor, Inc. 

Monjuvi and Minjuvi are registered trademarks of Incyte. 

About the inMIND Study[3]

A global, double-blind, randomised, placebo-controlled Phase 3 study, inMIND (NCT04680052) evaluated the efficacy and safety of Minjuvi (tafasitamab) in combination with rituximab and lenalidomide compared with placebo in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma (FL) Grade 1 to 3a or relapsed or refractory nodal, splenic or extranodal marginal zone lymphoma (MZL). The study enrolled a total of 654 adults (age ≥18 years), including 548 participants with R/R FL. 54 Australians participated in the study across 12 local trial sites around the country.

The primary endpoint of the study is progression-free survival (PFS) by investigator assessment in the FL population, and the key secondary endpoints are PFS in the overall population as well as positron emission tomography complete response (PET-CR) and overall survival (OS) in the FL population.

The clinical trial met its primary endpoint, with the data demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in comparison to placebo added to lenalidomide and rituximab. Patients receiving Minjuvi in combination with rituximab and lenalidomide achieved a median PFS by investigator assessment of 22.4 months (95% CI, 19.2-not evaluable [NE]) compared to 13.9 months (95% CI, 11.5-16.4) in the control arm (hazard ratio [HR]: 0.43 [95% CI, 0.32-0.58]; P<0.0001). The PFS assessed by an Independent Review Committee (IRC) was consistent with investigator-based results. Median PFS by IRC was not reached (95% CI, 19.3-NE) in the Minjuvi group versus 16.0 months (95% CI, 13.9-21.1) in the placebo group (HR: 0.41 [95% CI, 0.29-0.56].

Minjuvi was generally well-tolerated, with a manageable safety profile. Safety and tolerability were comparable with the addition of Minjuvi to lenalidomide in combination with rituximab. The most common adverse reactions in the Phase 3 study (≥20%) in patients receiving Minjuvi, excluding laboratory abnormalities, were respiratory tract infections (including COVID-19 infection and pneumonia), diarrhoea, rash, fatigue, constipation, musculoskeletal pain and cough.

About Specialised Therapeutics

Founded in 2007, Specialised Therapeutics is an independent specialty pharmaceutical company, providing novel therapies and technologies to patients in Australia, New Zealand and across Southeast Asia. Headquartered in Singapore, ST partners with global pharmaceutical, biotech and diagnostic companies to bring novel healthcare opportunities to patients who are impacted by a range of diseases. ST has built a strong track record of success, navigating complex regulatory, reimbursement and commercialisation environments in its diverse regions across multiple therapeutic areas. The ST mission is to provide specialty therapies where there is an unmet need to communities that would otherwise not have ready access to such therapies. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas.           

Additional information can be found at www.stbiopharma.com.

REFERENCES:

[1]. Australian Government, Department of Health, Disability and Ageing. PBS Schedule: PBS Publications & Downloads [August 2026].

[2]. NCCN Clinical Practice Guidelines in Oncology. B-Cell Lymphomas. Version 3.2026.

[3]. Sehn LH, et al. Lancet. 2026 Jan 10;407(10524):133-146.

[4]. Lymphoma Australia. Types of Lymphoma: Follicular Lymphoma. [Accessed July 2026].

[5]. Australian Institute of Health and Welfare (AIHW). Cancer Data in Australia: Prevalence Data Workbook – Blood Cancer Histology. [Accessed July 2026].

[6]. Therapeutic Goods Administration. Australian Register of Therapeutic Goods (ARTG): MINJUVI (tafasitamab). [Accessed July 2026].

[7]. MINJUVI Australian Product Information. 20 April 2026.

SOURCE Specialised Therapeutics

Tech giants Microsoft (MSFT +3.02%) and Meta Platforms (META +3.28%) have posted a disappointing stock market performance so far in 2026, with shares of both companies in the red as of this writing.

While Meta Platforms is down 14% this year, Microsoft has dropped 2%. Both Magnificent Seven stocks recently reported their quarterly results, and there was a stark contrast in the way the market reacted to their earnings reports. Let's see why that was the case.

Image source: The Motley Fool.

Microsoft stock soars after a solid report Shares of Microsoft popped more than 15% after the company released its fiscal 2026 fourth-quarter results (for the three months ended June 30) on July 29. Investors were happy with Microsoft's forecast that it will remain cash flow positive in fiscal 2027 despite investments in infrastructure to meet the growing demand for its artificial intelligence (AI) services.

Today's Change

(

3.02

%) $

13.62

Current Price

$

464.72

Microsoft projects $175 billion in capex for calendar 2026, below the $190 billion analyst estimate. It is also worth noting that Microsoft management remarked on the latest earnings call that its fiscal 2027 capex will increase year over year. So, the company's focus on prudently spending cash to build AI infrastructure has boosted investors' confidence in the stock, which explains the post-earnings pop.

Microsoft posted $332 billion in revenue in fiscal 2026, up by 18% from the prior year. Additionally, the company's non-GAAP earnings per share (EPS) increased by 22% year over year to $17.28. The tech giant has a large enough backlog to sustain healthy growth over the long run. It reported $678 billion in commercial remaining performance obligation (RPO) last quarter. The metric, which refers to the total value of contracts yet to be fulfilled at the end of a quarter, increased by 84%.

This tremendous backlog should support robust growth in Microsoft's cloud business over the long run, while the company's focus on keeping spending at reasonable levels should support bottom-line growth. This is why analysts have become bullish about Microsoft's earnings growth prospects.

Data by YCharts

The chart above indicates that Microsoft's earnings growth will eventually accelerate, which could set this tech stock up for healthy long-term gains.

Meta's aggressive spending has spooked investors Meta released its second-quarter results on July 29, the same day as Microsoft, but its stock headed in the opposite direction and fell over 9% the following day. It was easy to see why that was the case.

Today's Change

(

3.28

%) $

17.68

Current Price

$

556.71

Though Meta's Q2 revenue increased 28% year over year to $60.8 billion, its net income fell 14%. Meta's earnings per share of $6.18 landed well below the $7.22 consensus estimate. The company's aggressive AI infrastructure build-out led to a severe dent in the free cash flow, which fell to $784 million from $8.55 billion a year ago.

CEO Mark Zuckerberg pointed out on an earnings call with analysts that the company will "continue to invest aggressively in infrastructure" to support the growing demand for AI in its products and services. The company has narrowed its 2026 capex guidance to a range of $130 billion to $145 billion from the earlier range of $125 billion to $145 billion.

The higher floor suggests a 90% increase in capex this year at the midpoint, compared to last year's outlay of $72.2 billion. This increased spending explains why analysts have been reducing their bottom-line estimates for Meta. Consensus estimates project a 3% increase in Meta's earnings per share in 2026 to $32.12.

The earnings estimate was slightly higher at $33.07 per share a week ago. The EPS estimate for 2027 has also moved lower over the past week. So, the negative analyst sentiment could continue to weigh on Meta stock. Does this mean Microsoft is the better buy right now?

The discussion above indicates that Microsoft is currently poised to deliver stronger earnings growth than Meta. Also, investor sentiment is in Microsoft's favor following its latest quarterly report. Moreover, both stocks are almost in the same position when their valuations are considered, with Microsoft being slightly more expensive of the two.

Data by YCharts

So, it is easy to see that Microsoft is the better tech giant to buy right now, as its ability to deliver healthy earnings growth and attractive valuation should help it outperform Meta Platforms.

Micron Technology (MU -5.90%) has been one of the biggest beneficiaries of the booming demand for artificial intelligence (AI) compute. It's one of just a handful of companies that make memory chips, which have proven to be one of the biggest bottlenecks to expanding large language models and improving their performance. The company has seen its profit soar during the past few quarters as hyperscalers pay premium prices for its chips.

But the market has sold off Micron along with other semiconductor stocks since late June due to a mix of concerns about returns on AI spending and macroeconomic trends. The stock has fallen as much as 39% from its high. As a result, some investors may see an opportunity to invest in the stock. Here's what a $5,000 investment today could be worth in about two years.

Image source: Micron Technologies.

How much higher can Micron's earnings climb? As mentioned, Micron has seen its earnings soar in recent quarters due to higher prices for its memory chips. Prices climbed more than 60% on average compared to just three months prior during its fiscal third quarter (ended May 28).

The reason it can raise prices so much is that the market can absorb it. Hyperscalers have committed to hundreds of billions of dollars in capital expenditures this year alone. They've signed contracts to take hundreds of billions more in chips, infrastructure, and energy services during the next few years. The huge demand severely outstrips the current supply of memory chips across the entire industry, and Micron's management doesn't expect that shortage to abate until 2028 at the earliest.

But more supply is coming. Micron will spend more than $250 billion adding manufacturing capacity during the next decade. Its Virginia facility recently began producing legacy DRAM chips. Its first Idaho facility will begin producing high-end chips in mid-2027, with another facility coming in late 2028. Its New York facility broke ground this year and could start production in 2030.

Today's Change

(

-5.90

%) $

-51.63

Current Price

$

823.03

The competition is also adding capacity. SK Hynix and Samsung are combining to spend more than $1.3 trillion on production facilities during the next decade. Both are adding capacity to existing facilities and accelerating new fabrication plants that could increase production significantly by 2028. Additionally, Chinese competitor CXMT recently completed its initial public offering (IPO), raising up to $10 billion to expand its DRAM production capacity.

As more production capacity comes online, price increases will slow and eventually drop. Revenue growth will slow, and operating costs will rise as Micron and the competition invest more in production. That will lead to an earnings decline. The drop could be more severe if there's an oversupply, which could worsen if AI spending doesn't continue climbing as expected. As it stands, analysts expect Micron's earnings to peak in 2028 at about $178 per share. That's nearly 2.5 times the earnings estimated for fiscal 2026.

How much will a $5,000 investment today be worth in two years? Micron shares historically trade between 3 and 8 times earnings depending on the company's cyclical earnings peaks. That's because investors become increasingly aware of the potential drop in profit during the coming quarters as Micron approaches the peak of the cycle. A low-single-digit earnings multiple will quickly turn into a very high earnings multiple in the near future as earnings fall.

That's quite a wide range, though, and the multiple depends on how severe investors expect the drop in earnings will be. Micron and its competitors have taken steps to alleviate the cyclicality of their businesses by signing long-term agreements with some of their customers. Micron says its agreements cover about 20% of its DRAM volume and a third of its NAND volume from last quarter, and it's looking to sign more. That puts a floor on its volume and pricing in the future (and a ceiling on it in the present).

As such, Micron likely won't trade for a multiple at the low end by the time it hits its peak. A multiple in the middle, about 5 or 6 times earnings, is a fair estimate. That would put its stock price at about $1,000 by mid-2028. With the stock recently trading for just $740 per share, a $5,000 investment could be worth about $6,750 in two years.

To be sure, there's a broad range of possible outcomes. Personally, I want a wider margin of safety before buying Micron shares due to the high level of uncertainty facing the company. But for investors who think the current cycle could push earnings even higher or last longer than analysts currently expect, or that the downcycle won't be too severe, right now could be an opportunity to add shares.

Investors have long been bullish on Nvidia (NVDA +2.93%) for many reasons, but one that may not get a lot of direct attention is its backlog. Amid the massive demand for its AI accelerators, it accumulated a backlog of $500 billion in combined bookings for 2025 and 2026. Also, when CEO Jensen Huang was in Seoul in June, he stated that we are at the beginning of the AI boom, even as Nvidia stock has made massive gains over the last four years.

However, semiconductor stocks, including the chip giant, have pulled back in recent trading sessions as concerns about high capital expenditures (capex) and circular financing have given investors pause. Despite those concerns, investors should consider using this pullback to add shares. Here's why.

Image source: The Motley Fool.

The state of Nvidia Admittedly, the uncertainty surrounding Nvidia is understandable. The estimated $725 billion in planned capex by hyperscalers could raise doubts about access to credit. Moreover, Nvidia is an investor in many of its customers, leading to questions about whether the $500 billion is a true reflection of the backlog.

Nonetheless, other factors cast doubt as to whether Nvidia is really in trouble. Huang added that investors should be "very happy" since they can "buy at a discount." He appears to have a point. Its stock sells at a P/E ratio of 30, barely above the S&P 500 average of 29.

Despite that valuation and Huang's assertion about the AI boom, Nvidia is not trading at a premium. In the first quarter of fiscal 2027 (ended April 26), its revenue of $81.6 billion rose by 85% from year-ago levels. That led to $58.3 billion in net income, a 211% annual increase. Also, since revenue surged 65% higher in fiscal 2026, its quarterly growth is more than a one-time event.

Today's Change

(

2.93

%) $

5.71

Current Price

$

200.75

Considering Nvidia's growth rate, it likely does not need to artificially inflate its growth. Additionally, the "circular financing" is a reflection of its AI needs.

For example, it is an investor in the neocloud company CoreWeave, which is also a customer. In a technical sense, Nvidia does not "need" CoreWeave to grow.

Still, CoreWeave gives Nvidia a platform where it can more quickly deploy and test its hardware. Also, since the neocloud industry is new, the leading companies do not have the backing to scale quickly on their own.

With Nvidia's support, they can build faster, facilitating faster adoption of its technology. This means that such investments could pay off for Nvidia longer-term and, ultimately, ease the concerns of investors.

Moving forward with Nvidia Despite doubts, Nvidia's backlog is a reason to buy its stock.

Indeed, concerns about credit accessibility could slow growth and discourage some investors from buying its stock. Also, its so-called "circular financing" makes it look like Nvidia has to buy its growth.

However, the stock's P/E ratio seems to confirm that it sells at a discount. Also, it appears investments like its position in CoreWeave contribute to the improvement and rapid deployment of its hardware.

Thus, despite the concerns, investors should continue to believe in Nvidia's growth. Considering its comparatively low P/E ratio, investors have good reason to look past the uncertainty and take a position in the chip stock.

During the company's GTC conference in March, Nvidia (NVDA +2.93%) CEO Jensen Huang expressed confidence in the company's opportunity in the artificial intelligence (AI) chip market.

"We saw $500 billion of very high confidence demand and purchase orders for Blackwell and Rubin through 2026," Huang said. "I'm here to tell you that right now where I stand ... I see through 2027 at least $1 trillion."

Recent results indicate that Nvidia is very much on pace to hit that target -- but some risks could derail its momentum.

Jensen Huang speaking at a conference. Image source: Nvidia.

Nvidia's growth path Over the past year, Nvidia's data center revenue made up roughly 90% of its total revenue, and its Blackwell chips have been the main engine behind that growth. In the fiscal first quarter of 2027 (which ends in January), data center revenue grew 92% year over year to $75 billion.

In fiscal 2026, which mostly aligns with calendar 2025, Nvidia generated $216 billion in total revenue, with nearly $194 billion from data centers. Wall Street's consensus estimate currently forecasts total revenue of $394 billion this year and $561 billion next year -- about $1.17 trillion in cumulative total revenue since last year.

If Nvidia's data center segment remains about 90% of total revenue, that implies cumulative data center sales from last year -- largely from Blackwell and the new Rubin chips -- will exceed $1 trillion by the end of next year.

Management has stuck with that forecast. During the company's fiscal first-quarter earnings call, CFO Colette Kress said, "We are continuing to work vigorously on our supply chain ecosystem to address the incredible demand we see ahead of us, giving us full confidence in the $1 trillion in Blackwell and Rubin revenue we foresee from 2025 through calendar 2027."

However, Kress' comment about working on its supply chain implies the risks that could prevent Nvidia from meeting its forecast.

Today's Change

(

2.93

%) $

5.71

Current Price

$

200.75

Risks to watch A key risk is execution. AI demand has created one huge bottleneck from data center construction to memory and other components needed to build advanced chips. Demand for Nvidia's hardware looks enormous, but the open question is whether Nvidia can ship enough to meet it.

Another risk is competition from Nvidia's own customers, such as Amazon and Alphabet's Google, which are designing custom AI chips for their cloud platforms. Top cloud companies have previously made up about half of Nvidia's data center revenue. If those customers shift more workloads to in-house silicon, Nvidia's growth could slow.

That's also why Nvidia has been striking partnerships with neocloud and sovereign customers, including IREN and leading Japanese manufacturers. Nvidia needs to reduce its dependence on sales to big tech companies that are increasingly focusing on their own chips.

The $1 trillion cumulative sales target is still in play -- but it isn't guaranteed. If the data center market slows or supply constraints limit Nvidia's ability to fulfill orders, it could pressure growth and the stock.

John Ballard has positions in Amazon, Iren, and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, and Nvidia. The Motley Fool has a disclosure policy.

Born as a space company, Rocket Lab (RKLB +0.42%) is becoming more of a defense contractor as it matures.

Rocket Lab conducted its first-ever commercial satellite launch a little over eight years ago and has been ramping up its launches of small Electron rockets for both commercial and government customers ever since. In 2025, the company set a personal best, launching 21 times. Three of those launches were Hypersonic Accelerator Suborbital Test Electron (HASTE) test flights for the U.S. military.

Expect many more such military rocket launches in the future.

Image source: Getty Images.

Rocket Lab and Kratos Defense In March, Rocket Lab inked its biggest launch contract ever, promising to conduct 20 HASTE launches in cooperation with defense company Kratos Defense & Security Solutions over the next four years. The Department of Defense, in turn, agreed to pay Rocket Lab $190 million for its work -- $9.5 million per launch, or roughly a 13% premium to the company's usual Electron launch cost.

Given their suborbital trajectories, the HASTE tests appeared to be designed to demonstrate Rocket Lab's ability to use its Electron rockets as hypersonic weapons for the military.

But appearances can also be deceiving.

Today's Change

(

0.42

%) $

0.27

Current Price

$

64.95

Is Rocket Lab a space stock or a missile defense company? Prior to winning the HASTE contract (also known as MACH-TB 2.0 Task Area 1), Rocket Lab's other "biggest ever" contract win was an $816 million contract to build 18 missile warning satellites for the Space Force. (And before that, it won a $515 million contract -- also for missile defense satellites.)

Apparently, the U.S. military believes Rocket Lab is getting pretty good at missile defense -- so good, in fact, that it's giving Rocket Lab yet another chance to demonstrate its proficiency. And this time, Rocket Lab won't just detect hostile missiles.

It may try to shoot them down, too.

As announced last week, the Space Force has awarded Rocket Lab $266 million to conduct at least 12, and perhaps as many as 18, suborbital rocket launches under its Rocket Systems Launch Program (RSLP). The new test launches will be conducted from a new Rocket Lab launch base in the Pacific Spaceport Complex–Alaska (PSCA) in Kodiak, Alaska, but it's not 100% clear what they are supposed to accomplish. But Sir Peter Beck, Rocket Lab's CEO, dropped a heavy hint when he observed that "cadence, iteration, and relentless execution are essential to maturing America's missile defense capabilities."

To me, this suggests that the Space Force wants Rocket Lab to develop a family of hypersonic missiles to be used for missile defense -- and probably specifically for defense against Russian and Chinese hypersonic missiles currently in development. Rocket Lab may have a new area of hypergrowth for its business, with future military orders nearly doubling.

If I'm right, Rocket Lab is now a defense contractor.

BridgeBio Pharma (BBIO -2.50%) has already been one of biotech's biggest winners over the past two years (up 209% as of July 31). Yet Barclays analyst Eliana Merle believes the rally may not be over.

Merle recently reiterated her overweight rating and $157 price target, implying roughly 95% upside from where the stock is trading now. The bullish thesis here seems to center around the company's newly launched heart drug, Attruby, which could become a much larger commercial success than Wall Street currently expects.

Indeed, this is a reasonable expectation.

Image source: Getty Images.

Attruby is off to a strong start BridgeBio received FDA approval for Attruby in late 2024 to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive disease in which abnormal proteins accumulate in the heart, eventually leading to heart failure. Commercial adoption has been encouraging.

During the first quarter of 2026, BridgeBio generated $180.6 million in Attruby revenue in the U.S., helping total company revenue climb to $194.5 million. Management has also said more than 7,800 unique patients had received prescriptions from over 1,850 prescribers. And as awareness of the drug improves, the addressable market could expand well beyond today's treated population.

Today's Change

(

-2.50

%) $

-2.05

Current Price

$

80.09

Barclays may still be underestimating the opportunity Barclays' optimism is based partly on its belief that Attruby's commercial launch is outperforming Wall Street expectations. The firm projects $912 million in U.S. sales for 2026, roughly 10% above the consensus estimate of $826 million.

And BridgeBio isn't just a one-product company, either. It also has two potential approvals on the horizon. The FDA is reviewing BBP-418 for limb-girdle muscular dystrophy, with a decision expected by Nov. 27, 2026, and Encaleret, designed to treat autosomal dominant hypocalcemia type 1 (a rare condition caused by mutations in the CASR gene), which is scheduled for an FDA decision by May 8, 2027. Those programs could further diversify revenue while reducing reliance on a single commercial asset.

The valuation still leaves room for upside It's no secret that biotech stocks often look expensive before they become profitable, and BridgeBio is no exception. Yes, the company remains unprofitable today as it continues investing heavily in commercialization and late-stage development. That said, Wall Street expects revenue to nearly double this year to roughly $960 million, followed by another sharp increase in 2027 as Attruby sales continue ramping up. Analysts also expect BridgeBio to reach profitability next year.

Of course, that doesn't guarantee Barclays' $157 price target will be reached. Execution still matters. Attruby must continue gaining market share, additional pipeline programs need to deliver, and management has to prove it can successfully transition from a development-stage biotech into a multiproduct commercial company.

Still, I think Barclays' optimism is understandable. BridgeBio now has an approved blockbuster candidate generating meaningful revenue, several late-stage pipeline assets approaching important milestones, and analysts projecting rapid top-line growth over the next two years. If the company continues executing as it has so far, a significantly higher share price doesn't look unreasonable.

As of this writing, which is after the market closed on July 29, shares of Meta Platforms (META +3.28%) have fallen 10%. Earnings in Q2 (ended June 30) came in below estimates, while third-quarter revenue guidance was weaker than expected.

This extends the social media stock's losing streak. It's trading 26% below its all-time high from August 2025.

The market's attention in recent quarters has been directed to spending trends. Meta raised the lower end of its guidance for 2026 capital expenditures (capex) to $130 billion from $125 billion. But the upper end, $145 billion, was kept unchanged.

The business is betting it all on artificial intelligence (AI). Here's what investors need to know.

Image source: The Motley Fool.

Profits are under pressure During the second quarter, Meta reported operating income of $18.8 billion. This figure declined 8% year over year. That's because costs and expenses surged 55%. The gain is mostly coming from research and development, which exploded 68%.

Free cash flow (FCF) went from $8.5 billion in Q2 2025 to $784 million in the most recent quarter. Like the other hyperscalers, Meta is in the middle of a major capex super cycle. It's sparing no expense. The consensus view among analysts is that FCF will be negative in 2026 and 2027.

For what was such a wildly profitable business historically, this is a new normal that investors must get used to.

Meta's balance sheet is also not as robust as it once was. Its long-term debt of $83.7 billion is up from $58.7 billion at the end of last year. At the same time, cash and cash equivalents shrunk 57%.

There were also no share repurchases in the first six months of 2026.

Today's Change

(

3.28

%) $

17.68

Current Price

$

556.71

It all comes down to monetizing AI Investors received more color on Meta's plan to sell excess technical capacity to third-party customers. "We have quite a number of offers at a meaningful premium over what we paid for the compute," Zuckerberg said on the Q2 2026 earnings call. Because the industry is constrained on the supply side, the business can quickly generate revenue by offering its resources to the market.

But I think what matters most to Meta right now is how AI investments upgrade its core operations. "They're improving the experience for people using our apps, driving better performance for advertisers, and helping our teams build new experiences and ship faster," Zuckerberg added on the call.

Revenue grew 28% in Q2, an impressive figure for a company of this size. Both ad impressions and pricing jumped by double digits. And Meta's family of apps ended the quarter with 3.6 billion daily active users.

With up to $145 billion in capex on the line this year, investors should have high expectations, hoping the strong momentum continues. The stock's performance depends on the business delivering adequate returns from its AI efforts.

U.S. President Donald Trump gives thumbs-up as he walks to board Marine One following his arrival aboard Air Force One at Morristown Municipal Airport in Morristown, New Jersey, U.S., July 31,... Purchase Licensing Rights, opens new tab Read more

SummaryCompaniesCapital One says anti-money laundering review prompted closure of more than 300 Trump-affiliated accountsTrump Organization and Eric Trump sued in March 2025, alleging political debankingMiami federal court tossed two complaints but let plaintiffs file amended versionsSAN FRANCISCO, Aug 1 (Reuters) - Capital One Financial (COF.N), opens new tab hit back on Friday against a lawsuit over its decision to close ‌the Trump Organization's bank accounts years ago, stating that it did so after a review by anti-money laundering experts.

The disclosure marks the first time a bank has formally tied money laundering concerns to U.S. President Donald Trump's family business. Capital One is seeking to dismiss ​the case by casting doubt on claims of illegally debanking — or denying services on religious or political grounds — ​the Trump Organization.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

The Trump Organization and Capital One did not immediately respond to requests for ⁠comment.

Capital One has never accused the Trump Organization of illegal money laundering. But Friday's filing argues that "documents and Plaintiffs’ own ​allegations make clear that Capital One closed Plaintiffs’ accounts for anti-money laundering (“AML”) reasons. The closures were the result of months ​of analysis and a careful review by Capital One’s AML team in accordance with bank policies and regulatory guidance."

Capital One gave notice of its plans to close more than 300 Trump-affiliated bank accounts in March 2021. The Trump Organization and Eric Trump, the president’s son, filed ​a lawsuit in March 2025 in a Florida federal court, alleging the accounts were closed because of Capital One’s “woke” ​beliefs and its desire to benefit from the political mood after the January 6, 2021 riot at the U.S. Capitol.

'MISGUIDED' ALLEGATIONS: CAPITAL ONEThe ‌federal ⁠court in Miami has tossed two complaints in the Capital One case, but gave the plaintiffs opportunities each time to submit an amended complaint. Capital One said that the latest version, filed in July, “suffers from the same fundamental flaws as their prior two pleadings.”

Capital One said in Friday’s filing that the Trump Organization’s allegations of political pretext were “misguided” and “based on ​cherry-picked quotations unsupported by the full ​context” of documents submitted ⁠to the court.

“The transaction patterns identified by Capital One are among the types of activity flagged by federal banking guidance,” the filing said.

Since the start of Trump's second term, his ​administration has put pressure on some large banks, echoing conservative complaints that the institutions are ​deliberately targeting the ⁠political right.

Trump signed an executive order in August 2025 barring discriminatory debanking. In January, Trump filed a suit against JPMorgan Chase (JPM.N), opens new tab on the same grounds, underscoring the fraught policy environment Wall Street is navigating during the president’s second term.

In 2019, during his first term, Trump sued ⁠Capital One ​and Deutsche Bank in an attempt to prevent them from sharing financial ​records with Congress as part of a probe led by Democratic lawmakers. Anti-money laundering professionals at Deutsche Bank reportedly flagged a set of transactions, but ​executives ignored them; Deutsche Bank denied the report at the time.

Reporting by Kenrick Cai; Editing by Sergio Non and Rod Nickel

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Kenrick Cai is a correspondent for Reuters based in San Francisco. He covers Google, its parent company Alphabet and artificial intelligence. Cai joined Reuters in 2024. He previously worked at Forbes magazine, where he was a staff writer covering venture capital and startups. He received a Best in Business award from the Society for Advancing Business Editing and Writing in 2023. He is a graduate of Duke University. Reach him on Signal at @kenrick.01.

As of this writing, McDonald's (MCD +0.82%) stock sits at $270.64. The 52-week high is $341.75, so shares have given up about 21% -- and they now sit just 4% from the bottom of their yearly range. That's an unusual place to find one of the steadiest large businesses in the world, and to me, it's worth a look. At the current price, the stock offers a dividend yield of about 2.7%, and shares cost about 22 times earnings.

A decline like that usually means something went wrong. So, did the business change, or did just the price? The company's last four quarterly reports point one way.

Image source: Getty Images.

The business the stock left behind McDonald's has now posted positive global comparable sales (growth at restaurants open more than a year, the industry's cleanest measure of underlying demand) in each of its last four reported quarters. The streak runs 3.8% in the second quarter of 2025, 3.6% in the third, 5.7% in the fourth, and 3.8% in the first quarter of 2026. The fourth quarter also came with positive guest counts globally, meaning more transactions, not just higher checks.

The U.S. business, which investors have fretted over as lower-income consumers pull back, grew comparable sales 6.8% in the fourth quarter and 3.9% in the first quarter of 2026. The international side kept pace. International operated markets grew comparable sales 3.9% in the first quarter, and the developmental licensed markets, where local partners run the restaurants, grew 3.4%.

Profits followed. First-quarter revenue rose 9% year over year to about $6.5 billion, and operating income climbed 12% to nearly $3 billion -- a 45% operating margin. Earnings per share came in at $2.78, up 7%.

The full year of 2025 told the same story. Revenue rose 4% to $26.9 billion, operating income rose 6%, and earnings per share climbed 5% to $11.95.

That operating margin is the heart of the investment case. Most of McDonald's revenue doesn't come from selling burgers. Of that $26.9 billion in revenue, $16.5 billion came from its franchised restaurants -- rent and royalties collected from operators who put up their own capital and carry the restaurant-level costs.

That structure is why operating margins can sit in the mid-40% range and why profits could hold up through a consumer soft patch.

The loyalty program adds another layer of durability. Members generated over $9 billion in systemwide sales in the first quarter alone, across 70 markets, and loyalty sales for the trailing 12 months topped $38 billion.

Today's Change

(

0.82

%) $

2.20

Current Price

$

270.64

What the price pays for now At $270.64, McDonald's costs about 22 times earnings, based on earnings per share of $12.13 over the past 12 months. When the stock traded at its high of $341.75, those same earnings would have cost about 28 times. And trailing earnings were lower back then, so investors were actually paying more than that. Earnings per share went up over the past year. Only the price went down.

Put another way, the entire 21% decline came from investors paying less per dollar of McDonald's earnings, not from McDonald's earning less. The company's market value has dropped by about $50 billion, to about $191 billion, while the business behind it kept growing.

The dividend helps, too. At $7.44 per share annually, the payout yields about 2.7% at the current price, the direct result of a falling price meeting a steady dividend.

Of course, the picture isn't spotless. Comparable sales growth decelerated from the fourth quarter's 5.7% to 3.8% in the first quarter, and more than half of the first quarter's reported revenue growth came from currency moves rather than underlying demand: On a constant-currency basis, revenue grew 4%, not 9%. If U.S. traffic weakens from here, the comparable sales streak could get tested. And a price-to-earnings ratio of 22 isn't cheap, either. It's a reasonable price for a business of this quality, not a deep discount.

For me, that adds up to a buy. Nobody should buy McDonald's expecting a growth stock. But a business growing comparable sales every quarter, earning mid-40% operating margins on a largely franchised model, and yielding 2.7% is the kind of thing I'd rather own closer to its 52-week low than its high. I'd watch guest counts and U.S. comparable sales from here, since those would show cracks first. But I think the price finally fits the business.

In its fiscal third quarter (ended May 28, 2026), memory specialist Micron Technology (MU -5.90%) booked $41.5 billion of revenue -- more than it generated in any full fiscal year in its history. Its best year ever, fiscal 2025, brought in $37.4 billion.

The market spent Thursday deciding the story has further to run. Shares jumped 18.4% to $874.66 after Samsung told investors it expects the memory shortage to worsen in 2027 and continue into 2028. Micron's market value stood near $988 billion at Thursday's close, and the stock would need a climb of more than 40% to revisit its high of $1,255.

So, where could the stock realistically be in 2030? I think the honest answer has to take memory's history as seriously as its moment.

Image source: Micron.

What the boom is delivering The scale here is worth spelling out. Revenue of $41.5 billion was up nearly 350% year over year, from $9.3 billion, and up from $23.9 billion just one quarter earlier.

Profits are keeping pace. GAAP net income came in at $28.2 billion, helped by a gross margin of 84.6%. Operating cash flow was $25.4 billion, up from $11.9 billion the prior quarter and $4.6 billion in the year-ago period.

And even after $7.1 billion of capital expenditures, Micron generated $18.3 billion of adjusted free cash flow in a single quarter.

Even more, management expects a bigger quarter ahead. Guidance for the fiscal fourth quarter calls for roughly $50 billion of revenue, give or take a billion, at a gross margin near 86% -- with earnings of about $30.73 per share. Annualize that guided pace, and Micron is running at about $123 of earnings per share. At Thursday's close, the stock trades at about 7 times its guided earnings power. Measured against the past 12 months instead, shares go for about 20 times earnings. The distance between those two numbers is the market saying it doesn't trust the boom to hold.

The company also argues that this cycle is built differently.

"We believe our multi-year Strategic Customer Agreements will significantly enhance the durability and predictability of Micron's strong financial performance," said CEO Sanjay Mehrotra in the fiscal third-quarter earnings release.

Locked-in customer commitments, plus HBM4 (Micron's latest high-bandwidth memory for artificial intelligence (AI) accelerators) already shipping in high volume and its successor, HBM4E, pointed at 2027, form the case for this boom outlasting past ones.

What the cycle says about 2030 Zoom out, however, and memory's history argues for caution. In fiscal 2023, an oversupplied market roughly halved Micron's revenue to $15.5 billion, and the company lost $5.8 billion. That was three years ago -- same company, same industry. After all, booms in this business have always financed the supply that eventually ends them, and prices like today's are an open invitation for rivals to add capacity.

So build the range from both truths.

If contracted pricing holds and AI demand keeps absorbing supply into the decade, earnings power in the $120-per-share range could persist or even grow. Give that a multiple of 10 to 12 (arguably modest for a business this profitable), and the stock sits somewhere around $1,200 to $1,500 by 2030.

Today's Change

(

-5.90

%) $

-51.63

Current Price

$

823.03

If the cycle turns the way it always has historically, however, the math changes completely. Suppose earnings settle toward a mid-cycle level -- call it $40 to $60 per share, somewhere between fiscal 2025's $7.59 and today's triple digits. At 10 to 12 times, that's a stock somewhere between $400 and $700.

Split the difference, and the expected range is about $800 to $1,100, close to where the stock already trades. The midpoint of this range implies only modest returns from Thursday's $874.66. The market, it seems, has priced the middle path: several more boom quarters, then a slide toward normal.

That framing shapes what I'd do. I'd consider owning Micron here, but only modestly. The contracts and the product lineup make this boom sturdier than the last one, and 7 times guided earnings is not a price that requires perfection.

But memory has never gone in one direction for long, and I don't expect 2030 to arrive without another turn of the cycle. My base case is that the stock lands in the $800 to $1,100 range by then, with plenty of room to be wrong in either direction. If the fiscal fourth-quarter report (likely this fall) shows the supply agreements holding prices the way management promises, the higher end gets more believable.

SoFi Technologies (SOFI -0.97%) just can't get any market love these days. The neobank continues to demonstrate outstanding performance, and its stock continues to drop. After its second-quarter results were released on Wednesday morning, with record revenue and profits, SoFi stock fell another 13% as of this writing.

Is this just a continuation of negative sentiment that won't vanish? Or is the stock ripe for buying at the current price?

The cross-buy strategy is working SoFi is making its name as a major player in U.S. consumer banking. It continues to add new customers at a rapid pace, but it's also generating higher revenue through its cross-buy strategy. Management sees the company's differentiating factor as being a "one-stop shop" for all your digital banking needs, and as it onboards new customers and gets them to add new products, it's enjoying a flywheel effect of higher revenue and profits.

Image source: SoFi.

Here are some of the second-quarter highlights:

Adjusted net revenue increased 40% year over year to $1.2 billion. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose 44% to $358 million. Adjusted earnings per share (EPS) rose 50% to $0.12. Record loan originations of $14.8 billion, up 69%. Member growth was 35%, with 1.1 million new customers. Product growth was 42%, with 2.2 million new products. These last two points are important as they indicate the company's cross-sell strategy is working. Cross-buy accelerated to 51% in the quarter, with two new products for every new customer.

CEO Anthony Noto attributed this to the company's innovation engine. SoFi recently launched a slew of new products and features, like SoFi Coach, an artificial intelligence (AI) powered financial advisor, and Composer, a newly acquired investment AI agent.

Today's Change

(

-0.97

%) $

-0.16

Current Price

$

16.31

Although SoFi is not an investment bank, it does offer investing services, and it was one of the five brokerages chosen for the record-breaking Space Exploration Technologies initial public offering (IPO). It's also participating in the high growth of large investment banks that benefited from strong equities activity in the second quarter, and brokerage revenue increased 141%.

Why the market's down on SoFi stock It's not the first or even second time SoFi stock has dropped after an excellent earnings report. Usually, I'd say that as an expensive stock, there's so much priced into the stock that any imperfection will send it down. But at 19 times next year's earnings, SoFi looks quite reasonably priced for the kind of growth it's demonstrating.

What seems to have it riled up right now is that while management raised the full-year revenue outlook, it kept the profit outlook steady. Management says, however, that it now anticipates two rate hikes instead of two rate decreases, which drove its original guidance, and it's also plowing profits back into the business to capitalize on its opportunity.

I'm bullish on SoFi long-term, but if you do buy it now, be prepared for volatility along the stock's journey.

Uber has partnered with — and in some cases made direct investments in — more than 30 autonomous vehicle companies over the past two years. And it’s taking a global approach.

Here, TechCrunch tracks every one of those moves in one place. But first, a bit of history. 

Uber was, at one time, developing and testing its own autonomous vehicle (AV) technology. The company, then led by Travis Kalanick, created Uber Advanced Technologies Group (ATG) in 2014 and recruited dozens of researchers from Carnegie Mellon University’s robotics program. 

Two years later, Uber acquired Otto, a self-driving truck company founded by former Google self-driving engineer Anthony Levandowski, Lior Ron, Don Burnette (who has since gone on to found Kodiak AI), and Claire Delaunay. Uber also began testing its AVs on public streets in 2016 across California, Pittsburgh, and Arizona. 

All of that progress unraveled across three defining moments: Waymo’s trade secrets lawsuit against Uber, the resignation of Kalanick in 2017, and a fatal crash in Tempe, Arizona, in 2018 involving its self-driving Volvo XC90, which struck and killed a pedestrian. (The vehicle was in autonomous mode, and a human safety operator behind the wheel at the time wasn’t paying attention.) Uber suspended its testing and reorganized the program, although it never truly returned to its mission.

After Dara Khosrowshahi took the wheel at Uber, the company went through a reset. 

In 2020, Uber walked away from all of its moonshots, including autonomous vehicles, to focus on its core businesses of ride-hailing and delivery using human-driven vehicles. Uber sold Uber ATG to Aurora, Jump to Lime, and Elevate to Joby Aviation. It didn’t completely divest, though. Uber kept equity stakes in all of them.

Just two years later, Uber crept back in and started making AV deals. The deal flow picked up in earnest in 2024. Below is the full list, which TechCrunch will keep updated as Uber makes new moves.

Aurora Image Credits:Aurora Innovation Uber has been connected with Aurora since 2020 when, as mentioned above, it sold its Uber ATG unit to the company. Uber received equity in Aurora as part of that deal and still owns that stake. As of this past April, Uber, through its holding company Neben Holdings, owns 325.97 million Aurora Class A shares, representing a 19.7% Class A equity stake and 6.9% voting power, according to SEC filings. 

Uber Freight, the logistics business spun out of Uber in 2018, announced in June 2024 a multi-year collaboration with Aurora that expanded upon an existing pilot program. In May 2025, the companies said Aurora’s self-driving trucks had been completing roundtrip hauls between Dallas and Houston via the Uber Freight platform. 

Autobrains In June 2026, the companies announced plans to launch a robotaxi program in Munich, pending regulatory approval. The partnership lacks some details, such as what vehicle will be used. The companies pitched this as an OEM-agnostic model. Vehicles will be equipped with Israel-based Autobrains’ agentic AI driving system, which runs on Nvidia’s Drive Hyperion platform. The robotaxis will be available via Uber’s app. 

Avomo Avomo, a European company that was previously known as Moove Cars, is an autonomous fleet operator partner. Uber actually took a 30% stake in Avomo in 2021. 

And while Avomo might not have the same name recognition as other players, it is embedded in Uber’s AV business. For instance, it is the company responsible for managing fleet services such as vehicle cleaning, maintenance, inspections, charging, and depot operations for the Waymo-Uber partnership in Austin. Avomo also handles fleet operations for Uber as part of its robotaxi service agreement with WeRide in Madrid, which was announced in June 2026. 

Important note: don’t mistake Avomo (formerly Moove Cars), for Moove, an African company that manages Waymo’s AV fleet in Phoenix.

Avride Image Credits:Avride Avride, the Yandex spinout now under parent company Nebius Group, announced a multi-year deal with Uber in October 2024 to bring Avride’s sidewalk delivery robots and autonomous vehicles to both Uber’s delivery unit, Uber Eats, and Uber’s ride-hailing app. 

In February 2025, Uber shared in its fourth-quarter earnings that Uber Eats orders in Austin and Dallas were being delivered via autonomous sidewalk robots in partnership with Avride. Avride disclosed in fall 2025 that it had secured strategic investments and commercial commitments worth $375 million from Uber and Nebius. Neither company provided details on the investment and how much was capital. 

By the end of 2025, Avride robotaxis — built on Hyundai IONIQ 5s outfitted with Avride’s self-driving system — were available on the Uber app in Dallas. The National Highway Traffic Safety Administration opened an investigation into Avride in May 2026 after identifying more than a dozen crashes and one minor injury.

As of this past June, these were not driverless and still had a human safety operator behind the wheel. 

Baidu Uber announced a multi-year strategic partnership with the Chinese tech giant in July 2025. Under the agreement, thousands of Baidu’s Apollo Go autonomous vehicles will be deployed on the Uber platform in multiple markets outside the U.S. and mainland China. Those deployments were set to start in Asia and the Middle East later in 2025, the companies said at the time.

In late 2025, Baidu said it would start testing Apollo Go robotaxis in London in the first half of 2026 through its partnership with Uber. As of June, those tests had not begun. 

Cartken  The sidewalk delivery robot company started working with Uber in 2022, announcing a partnership to deliver food in Miami, with plans to add more cities in 2023. The two companies expanded to commercial deliveries in Fairfax, Virginia that same year and, in February 2025, announced that they were delivering food in Osaka, Japan, using Cartken robots.

Cartken shifted its focus to industrial robots by summer 2025. The company said it would maintain its food and consumer last-mile delivery business, but had no plans to expand it. 

Coco A Coco robot in Santa Monica, California on August 14, 2024.Image Credits:James D. Morgan / Contributor / Getty Images In 2024, the two companies announced a partnership to use Coco’s sidewalk robots to deliver food for Uber Eats customers, starting in Los Angeles. The partnership expanded to neighborhoods in Miami in April 2025.

Cruise Uber and GM’s Cruise announced a strategic partnership in August 2024 to bring Cruise’s robotaxis onto the Uber app in 2025. That announcement was notable for Cruise, which had gone through a major overhaul, including layoffs and the resignation of its co-founders after one of its robotaxis struck a pedestrian in October 2023.

The Cruise reboot never got off the ground; in December 2024, citing high costs and mounting competition, GM pulled the plug on Cruise’s robotaxi business entirely and folded the unit into its broader engineering operations.

The partnership no longer exists because — welp — Cruise itself doesn’t, at least not as a robotaxi company. But at one time, the two companies had struck a deal.

Flytrex Uber announced in September 2025 a partnership with drone delivery company Flytrex. The partnership also included a small investment in Flytrex, although the amount was not disclosed.

Hertz  Hertz isn’t developing autonomous vehicle tech, but it’s still worth including the rental car company here. In April of this year, Uber formed strategic fleet partnerships with Hertz and its affiliated operating company Oro Mobility. 

This deal is part of Uber’s plans to launch a premium robotaxi service using Lucid vehicles equipped with Nuro’s self-driving system. Hertz has been tasked with day-to-day fleet management, including charging, maintenance, repairs, cleaning, and depot staffing. 

Lucid Image Credits:Uber Uber has put real money behind EV maker Lucid Motors. Uber announced plans in 2025 to launch a premium robotaxi service using robotaxi-ready vehicles from Lucid. Initially, Uber said it would invest $300 million into Lucid and separately buy at least 20,000 of its Lucid Gravity SUVs over six years. The vehicles will be equipped with Nuro’s self-driving system. 

In April, Uber upped its order and investment. Lucid received another $200 million from Uber, which also increased its minimum order to 35,000 vehicles. The order includes Lucid’s upcoming mid-sized platform. Uber now owns more than 11% of Lucid as part of investments it has made alongside the vehicle orders.

May Mobility  Image Credits:May Mobility The Michigan-based autonomous vehicle startup reached an agreement with Uber in May 2025 to deploy its AVs through the app by the end of that year, starting in Arlington, Texas.

Uber and May Mobility announced plans at the time to expand to other U.S. markets in 2026 and “deploy thousands of AVs” over “the next few years,” according to the startup.

As of June, Arlington, Texas, remains the only market where customers using the Uber app can hail a May Mobility vehicle. 

Mercedes In January of this year, Mercedes-Benz announced it was collaborating with Nvidia to create a robotaxi ecosystem using self-driving S-Class sedans that would be on the Uber ride-hailing platform. No specific cities have been announced.

Momenta  The Chinese autonomous driving tech company reached an agreement with Uber in May 2025 to add its robotaxis to the app, starting in Europe in early 2026, with safety operators on board.

A few months later in September 2025, the Beijing-based company and Uber said they would start testing robotaxis in Munich, Germany in 2026. 

Motional  A Hyundai Ioniq 5 powered by Motional on Uber’s network in Las VegasImage Credits:Motional Motional, a subsidiary of Hyundai, has been working with Uber in some form since 2021 when the companies announced plans to launch autonomous deliveries in Santa Monica. This was considered a pilot and never became a commercial program or used fully driverless vehicles. 

The companies expanded the partnership in October 2022 with a 10-year operating agreement that will eventually roll out to major cities across North America; Las Vegas and Los Angeles were among the first named cities. While Motional and Uber remain partners, a commercial driverless service (meaning no human safety operator behind the wheel) has yet to materialize. 

Motional went through a reboot in 2024, taking a new AI-centric approach to its self-driving system. In March 2026, Motional’s self-driving Hyundai Ioniq 5 vehicles were added to the Uber app in Las Vegas for autonomous rides to and from five areas of the city. Human safety monitors are still riding along

New Horizon New Horizon is a fleet management company involved in Uber’s agreement with Baidu to bring the Chinese company’s Apollo Go autonomous ride-hailing service to Dubai.

Nissan Nissan is part of Uber’s partnership agreement with Wayve. In March of this year, Uber announced plans to add self-driving Nissan Leaf EVs to its network in Tokyo, powered by Wayve’s tech. (See the Wayve entry below for more.)

Nuro Image Credits:Nuro The self-driving tech startup has been tied to Uber since at least 2022, but the relationship has changed. Initially, Nuro was developing a custom-built delivery vehicle designed for the roadway. Uber and Nuro announced a 10-year partnership in 2022 to launch autonomous deliveries in Mountain View, California, and Houston starting that fall. 

Nuro pivoted away from the delivery vehicle and decided to focus on licensing its self-driving tech to automakers and robotaxi operators. Uber stuck with Nuro and in 2025 announced a landmark deal to launch a premium robotaxi service using Lucid Gravity SUVs equipped with the startup’s self-driving system. 

San Francisco will be the first market. In June of this year, the companies announced the second market will be Houston. Uber has also invested in Nuro. Sources familiar with the financial terms have told TechCrunch that Uber’s total commitment to Nuro, which includes its participation in the startup’s Series E round in 2025 and future milestone-based investments, is about $500 million.

Nvidia Uber first publicly talked about Nvidia in January 2018, a different era for both companies. Uber picked Nvidia to provide AI computing for its autonomous software. With Uber’s in-house AV program sold off in 2020, that deal ended. 

Fast forward to CES 2025, when Uber said it would use Nvidia’s generative world model simulation tool, Cosmos, and cloud-based AI supercomputing platform, DGX Cloud, to support the development of AV tech. Uber didn’t share many details at the time about how it planned to use these Nvidia tools. 

In October 2025, Uber and Nvidia announced plans to use Nvidia’s Hyperion autonomous platform to accelerate Uber’s robotaxi program. As part of that announcement, Stellantis committed to delivering at least 5,000 Nvidia Drive-powered vehicles to Uber for robotaxi operations in the U.S. and internationally — one of the first automakers to do so.

In March of this year, the companies expanded the partnership and announced plans to launch a global fleet of entirely Nvidia software-driven autonomous vehicles, starting in Los Angeles and San Francisco in the first half of 2027 and scaling across 28 cities globally by 2028. The companies said the vehicles will run Nvidia’s Drive Hyperion platform and use Alpamayo, Nvidia’s family of open-source AI models, datasets, and simulation tools designed to handle complex driving situations.  

Pony.ai Image Credits:Uber / Rimac The Guangzhou, China-based company and Uber announced a partnership in May 2025 with an eye on the Middle East. The companies planned to launch a pilot that year that would make

Pony.ai’s robotaxis (with a safety operator on board) available on the Uber app.

In March 2026, Uber, Pony.ai, and Croatian company Verne announced plans to launch a commercial robotaxi service in Europe, starting in Zagreb, Croatia. Pony.ai will supply the autonomous driving system and a robotaxi called the Arcfox Alpha T5 that was developed with Chinese automaker BAIC. Verne will own and operate the fleet, and Uber will provide its vast ride-hailing network. 

Rivian  This unexpected deal, which was announced in March 2026, could be worth up to $1.25 billion for Rivian. Under the agreement, Rivian will build thousands of robotaxis based on its new R2 SUV and will be equipped with the EV maker’s self-driving system, which is still under development. 

Uber made an initial $300 million investment in Rivian and is “expected to purchase 10,000 fully autonomous R2 robotaxis” ahead of a planned rollout in San Francisco and Miami in 2028. The two companies said at the time they plan to launch the robotaxis in “25 cities in the U.S., Canada, and Europe by the end of 2031.” The fleet will be exclusively available on Uber’s network.

Serve Robotics Image Credits:Uber The sidewalk delivery robot startup is rooted in Uber, sort of. In 2020, Uber acquired on-demand delivery startup Postmates. The following year, the robotics division known as Postmates X spun out as an independent company called Serve Robotics.

Uber also invested in Serve, which went public in 2024 through a merger with a blank-check company.  

Uber Eats has used Serve Robotics’ robots for a few years in the United States. 

Starship Technologies Sidewalk delivery robot company Starship Technologies struck a deal with Uber’s delivery unit Eats in November 2025. Under the deal, Starship robots will deliver food orders via the Uber Eats app in multiple European countries in 2026 and eventually expand to the U.S. in 2027.

Stellantis The automaker announced in June 2026 a deal with self-driving startup Wayve, and Uber to jointly develop and deploy driverless robotaxis. Stellantis and Wayve, which Uber has invested in, were already working together. This deal brings all of the components together: automaker, self-driving tech, and ride-hailing network.

The companies have agreed to work together on vehicle integration, testing, and validation before Stellantis-made vehicles equipped with Wayve’s tech are deployed in the real world, and specifically across Europe and North America.

Tawasul The UAE-based Tawasul is another operator andpartnered with Uber in 2024 to provide fleet management services for Uber’s WeRide robotaxi service in Abu Dhabi. 

Torc Robotics Uber Freight, the logistics company that spun out of Uber in 2018, announced a partnership in late December with Torc Robotics, a self-driving trucks company that was acquired by Daimler in 2019. The partnership has largely focused on data.

Torc has used Uber Freight to analyze volume patterns, shippers’ networks, and other data that will help it identify the most effective lanes and most suitable commercial applications for autonomous trucking deployment.

Verne  Uber’s relationship with Verne is pretty fresh. The company, formed by Rimac Group founder Mate Rimac, reached an agreement in March 2026 to launch a commercial robotaxi service in Europe, starting in Zagreb, Croatia. Pony.ai, the third partner, is supplying the self-driving system. Verne will own and operate the fleet of vehicles made by Chinese automaker BAIC.

Uber also planned to invest in Verne, although the terms have not been disclosed. 

Volkswagen/MOIA Image Credits:MOIA/Volkswagen / Volkswagen’s subsidiary MOIA America and Uber announced plans in 2025 to launch a commercial robotaxi service using autonomous versions of Volkswagen’s electric ID. Buzz minivan. The companies said robotaxis will launch in multiple U.S. cities over the next decade. Los Angeles is the first city.

The companies, which have set up a joint facility in Los Angeles for day-to-day fleet operations, said in April 2026 that a robotaxi service would launch later in the year, with a human safety operator on board. Driverless operations are expected to begin in 2027.

Volvo Autonomous Solutions Uber Freight, which connects companies that need to ship goods with truck drivers and fleet carriers, first partnered with Volvo Autonomous Solutions in 2023. Two years later, the companies said the partnership was moving “out of the planning stage and delivering tangible results.”

Volvo’s VNL Autonomous truck, which was built with redundancies to support self-driving tech developed by Aurora Innovation, began delivering loads for Uber Freight customers between Dallas and Houston. Those routes have since expanded.

Waabi The Uber and Waabi relationship is also a deep cut. The founder and CEO, Raquel Urtasun, previously worked at Uber as chief scientist at its autonomous vehicle division, Uber ATG, which Uber sold to self-driving trucking firm Aurora Innovation in 2020.

Urtasun founded Waabi in 2021 with an initial focus on self-driving trucks. Uber was among the investors that participated in its $83.5 million Series A round. Waabi and Uber got a lot closer in 2026. In January, Waabi raised $1 billion — $750 million in a Series C round and about$250 million in milestone-based capital from Uber to support the deployment of robotaxis equipped with Waabi’s self-driving system. 

Waymo Image Credits:Waymo/Uber The Alphabet-owned company first partnered with Uber in May 2023, when it agreed to bring some of its robotaxis on the Uber platform, starting in Phoenix. The relationship in Phoenix is limited since Waymo customers can also directly hail a robotaxi using the company’s own app.

The following year, the companies announced an expansion to Austin and Atlanta, although this time the Waymo robotaxis could only be accessed via the Uber app. The Austin service launched in March 2025, followed by Atlanta by June 2025. 

The relationship has not expanded since; it has actually shrunk. The companies ended their Phoenix partnership in last month, in July. Waymo is now working to get out of its contract with Uber, which doesn’t end until May 2028.

Wayve Image Credits:Nissan The buzzy UK self-driving startup has both partnered with and received capital from Uber. In February 2026, Wayve raised $1.2 billion in a round that included returning backers Microsoft, Nvidia, and Uber. The total raise could reach $1.5 billion thanks to another $300 million from Uber contingent on deploying robotaxis, beginning in London.

In March 2026, Uber announced plans to add self-driving Nissan Leaf EVs to its network in Tokyo, powered by Wayve’s tech. A pilot has been scheduled for late 2026. Under the deal, Wayve will integrate its AI-powered, self-driving software into a Nissan Leaf, which will be available on Uber’s ride-hail network in Japan.

WeRide   Image Credits:WeRide The Chinese robotaxi company is one of Uber’s more prolific partners. It publicly disclosed the partnership in September 2024 and shared plans to bring WeRide robotaxis to the Uber platform, starting in Abu Dhabi. The service launched in December 2024 with human safety operators and went driverless in November 2025. WeRide robotaxis launched on the Uber app in Dubai in late 2025. 

Uber expanded the partnership to bring WeRide’s AVs to 15 more cities by 2030, including in Europe. In these cities, WeRide’s robotaxis will be available through the Uber app, and Uber will be responsible for fleet operations. As part of the expansion, Uber increased its investment into WeRide by $100 million. Uber has since revealed some of those cities, including Madrid and Zurich.

In February 2026, the partnership expanded again with the companies agreeing to deploy at least 1,200 robotaxis across the Middle East. The deployment, which will span Abu Dhabi, Dubai, and Riyadh, Saudi Arabia is expected to be completed as soon as 2027.

Zoox The Amazon-owned company is an Uber latecomer. The companies announced a strategic partnership in March 2026 to deploy Zoox robotaxis on the Uber app in Las Vegas this year and in Los Angeles in 2027.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Lucid Group (LCID -9.11%) stock soared this week ahead of its earnings report on Aug. 4. That wasn't the reason for the rally, though. A billionaire investor bought a stake in the company, helping shares jump 17% from last Friday's close, according to data provided by S&P Global Market Intelligence.

Lucid's largest shareholder is Saudi Arabia's sovereign wealth Public Investment Fund (PIF). The PIF has participated in multiple investment rounds, and the electric vehicle (EV) maker has a manufacturing facility in the Kingdom.

That plant currently handles vehicle assembly using parts imported from the U.S., but Lucid also plans to produce vehicles there in full. This week, a well-known Saudi investor also took a stake in the EV maker.

Image source: The Motley Fool.

Saudi billionaire Prince Alwaleed bin Talal Al Saud revealed a passive 5% ownership in Lucid Group in a Securities and Exchange Commission (SEC) filing on July 28, 2026. He acquired 19.5 million Class A common shares during a market downturn when Lucid's market value dropped below $2 billion.

The Saudi prince is known for his large investments in big, global tech companies. That explains why investors jumped into Lucid after learning of his stake. But blindly following another investor, no matter how successful, isn't necessarily a smart strategy.

Lucid's upcoming report on Tuesday, Aug. 4, after the market closes, is what investors should focus on. The company is counting on its new Gravity SUV and self-driving technology to boost sales. Any related news is what should guide investors' next move with Lucid stock.

Howard Smith has positions in Lucid Group. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Store

SubscribeSign In

My Subscriptions

Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD LiveCustomer Center

My Stock Lists

Email Preferences

Help & Support

Sign Out

Search stocks or keywords

Sections

My IBD

MARKET TREND

STOCK LISTS

STOCK RESEARCH

NEWSECONOMY

VIDEOS & PODCASTS

HOW TO INVESTEDUCATIONAL RESOURCESStoreMy Products

Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD Live

Recently Searched

Banking Giant JPMorgan Leads 19 Newcomers To IBD Best Stock Lists

Positive Market Shift, But Watch For This; Amazon, Alphabet, CrowdStrike In Focus

Stock Market Gains Even As Apple Crumbles; Jobs Report, AMD Earnings Loom SpaceX releases its second-quarter earnings late Tuesday, marking the rocket-maker's first report since its public debut in June. The results should detail the Starbase, Texas-based company's accelerating launch programs, Starlink growth and artificial intelligence developments. The report arrives as SPCX stock last week fell to post-IPO lows. Beyond financial figures and performance metrics, analysts and investors await updates from Elon…

Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8

Posted by Defense World Staff on Aug 1st, 2026

Audent Global Asset Management LLC lowered its stake in shares of Amazon.com, Inc. (NASDAQ:AMZN) by 20.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,271 shares of the e-commerce giant’s stock after selling 4,970 shares during the quarter. Amazon.com comprises approximately 4.2% of Audent Global Asset Management LLC’s holdings, making the stock its 7th largest holding. Audent Global Asset Management LLC’s holdings in Amazon.com were worth $4,014,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of AMZN. Brighton Jones LLC raised its stake in shares of Amazon.com by 10.9% in the fourth quarter. Brighton Jones LLC now owns 4,036,091 shares of the e-commerce giant’s stock valued at $885,478,000 after purchasing an additional 397,007 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in Amazon.com by 4.1% during the fourth quarter. Revolve Wealth Partners LLC now owns 25,045 shares of the e-commerce giant’s stock worth $5,495,000 after buying an additional 986 shares in the last quarter. Bank Pictet & Cie Europe AG increased its holdings in Amazon.com by 2.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 2,016,869 shares of the e-commerce giant’s stock valued at $442,481,000 after buying an additional 54,987 shares during the period. Highview Capital Management LLC DE increased its holdings in Amazon.com by 5.5% in the 4th quarter. Highview Capital Management LLC DE now owns 28,975 shares of the e-commerce giant’s stock valued at $6,357,000 after buying an additional 1,518 shares during the period. Finally, Liberty Square Wealth Partners LLC acquired a new position in shares of Amazon.com in the 4th quarter valued at $2,153,000. 72.20% of the stock is owned by institutional investors.

Analyst Ratings Changes Several research analysts recently issued reports on AMZN shares. Guggenheim reissued a “buy” rating and issued a $320.00 price target (up from $300.00) on shares of Amazon.com in a research report on Thursday, April 30th. Scotiabank reaffirmed an “outperform” rating and set a $325.00 price objective (up from $275.00) on shares of Amazon.com in a report on Thursday, April 30th. HSBC reissued a “buy” rating and issued a $310.00 target price on shares of Amazon.com in a report on Friday. Rosenblatt Securities raised their target price on Amazon.com from $332.00 to $345.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $300.00 price target on shares of Amazon.com in a research report on Friday. Fifty-six investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $322.12.

Check Out Our Latest Report on AMZN

Insider Transactions at Amazon.com In other news, CEO Douglas J. Herrington sold 27,500 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $275.00, for a total value of $7,562,500.00. Following the sale, the chief executive officer directly owned 471,361 shares in the company, valued at $129,624,275. The trade was a 5.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Shelley Reynolds sold 2,363 shares of the company’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $262.38, for a total value of $620,003.94. Following the transaction, the vice president directly owned 119,780 shares of the company’s stock, valued at $31,427,876.40. This represents a 1.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 135,719 shares of company stock worth $36,438,002. Company insiders own 8.90% of the company’s stock.

Trending Headlines about Amazon.com Here are the key news stories impacting Amazon.com this week:

Positive Sentiment: Amazon reported record quarterly sales of $200.6 billion, up nearly 20% year over year, while earnings per share of $5.75 significantly exceeded the $1.82 consensus estimate. Operating income rose 43% to $27.5 billion. Amazon second-quarter results Positive Sentiment: AWS revenue accelerated 37% to $42.2 billion—its fastest growth in 18 quarters—beating expectations as enterprise AI demand strengthened. The result helped ease concerns that Amazon’s massive AI infrastructure investments would not produce adequate returns. Amazon AWS growth Positive Sentiment: Advertising revenue climbed 26% to approximately $19.8 billion, while stronger e-commerce activity and robotics-supported fulfillment added to the broad-based quarterly beat. Positive Sentiment: Multiple firms raised their price targets following the results, including JPMorgan to $365, Benchmark to $400, Truist to $350, and RBC to $330. Analysts cited accelerating AWS growth, AI monetization and margin potential. Amazon analyst price targets Positive Sentiment: Amazon completed the remaining $35 billion of its planned OpenAI investment, bringing its total commitment to $50 billion. The partnership could support future AWS demand, although it also increases capital commitments. Amazon OpenAI investment Neutral Sentiment: Amazon raised its 2026 capital-spending outlook to $220 billion to expand AI and cloud capacity. Management sees demand extending into 2028, but the scale of spending will keep free cash flow and funding requirements under scrutiny. Neutral Sentiment: The company expects third-quarter revenue of $197 billion to $202 billion, below the roughly $204.6 billion analyst consensus, creating a potential near-term headwind despite the strong quarter. Negative Sentiment: Amazon faces consumer lawsuits alleging misleading seafood sustainability claims and the sale of protein powder allegedly contaminated with heavy metals. The cases could create legal, reputational and compliance costs, though their financial impact is currently unclear. Amazon consumer lawsuit Amazon.com Price Performance Shares of AMZN opened at $271.58 on Friday. The stock has a 50 day simple moving average of $245.70 and a 200 day simple moving average of $236.22. Amazon.com, Inc. has a 52-week low of $196.00 and a 52-week high of $278.56. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.01 and a current ratio of 1.18. The firm has a market capitalization of $2.92 trillion, a PE ratio of 21.85, a P/E/G ratio of 1.75 and a beta of 1.46.

Amazon.com (NASDAQ:AMZN – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The e-commerce giant reported $5.75 earnings per share for the quarter, beating the consensus estimate of $1.82 by $3.93. Amazon.com had a net margin of 17.44% and a return on equity of 19.59%. The company had revenue of $200.61 billion during the quarter, compared to analysts’ expectations of $197.03 billion. During the same quarter in the prior year, the company earned $1.68 earnings per share. The business’s quarterly revenue was up 19.6% compared to the same quarter last year. Sell-side analysts predict that Amazon.com, Inc. will post 7.84 EPS for the current fiscal year.

Amazon.com Profile (Free Report)

Amazon.com, Inc is a diversified technology and retail company best known for its e-commerce marketplace and broad portfolio of consumer and enterprise services. Founded by Jeff Bezos in 1994 and headquartered in Seattle, Washington, the company launched as an online bookseller and expanded into a global retail platform that sells products directly to consumers and provides a marketplace for third-party sellers. Over time Amazon has grown beyond retail into areas including cloud computing, digital media, devices and logistics.

Key businesses and offerings include Amazon’s online marketplace and fulfillment services, the Amazon Prime membership program (which bundles expedited shipping with streaming and other benefits), Amazon Web Services (AWS) which supplies on-demand cloud computing and storage to businesses and public-sector customers, and a range of content and advertising services such as Prime Video and Amazon Advertising.

Featured Stories Five stocks we like better than Amazon.com Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case Apple’s Record Quarter Could Not Outrun Its Guidance Problem McKesson’s Compounding Keeps Adding Up Want to see what other hedge funds are holding AMZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amazon.com, Inc. (NASDAQ:AMZN – Free Report).

Receive News & Ratings for Amazon.com Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amazon.com and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECitigroup Has Lowered Expectations for Vertiv (NYSE:VRT) Stock Price

NEXT HEADLINE »Avidity Partners Management LP Purchases Shares of 20,000 Gilead Sciences, Inc. $GILD

Argent Capital Management LLC trimmed its holdings in JPMorgan Chase & Co. (NYSE:JPM) by 9.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 204,904 shares of the financial services provider’s stock after selling 21,859 shares during the quarter. JPMorgan Chase & Co. comprises approximately 1.9% of Argent Capital Management LLC’s portfolio, making the stock its 15th biggest position. Argent Capital Management LLC’s holdings in JPMorgan Chase & Co. were worth $60,275,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Timmons Wealth Management LLC acquired a new stake in JPMorgan Chase & Co. in the fourth quarter valued at $27,000. MBM Wealth Consultants LLC acquired a new position in shares of JPMorgan Chase & Co. during the 1st quarter worth $29,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of JPMorgan Chase & Co. during the 4th quarter worth $32,000. Osbon Capital Management LLC purchased a new position in shares of JPMorgan Chase & Co. in the 4th quarter valued at about $35,000. Finally, Turning Point Benefit Group Inc. purchased a new position in shares of JPMorgan Chase & Co. in the 3rd quarter valued at about $35,000. 71.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes Several equities research analysts have recently commented on JPM shares. Autonomous Res decreased their price target on JPMorgan Chase & Co. from $360.00 to $324.00 and set a “neutral” rating on the stock in a research note on Monday, April 6th. Keefe, Bruyette & Woods raised their price objective on JPMorgan Chase & Co. from $370.00 to $384.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Citigroup boosted their price objective on shares of JPMorgan Chase & Co. from $325.00 to $360.00 and gave the stock a “neutral” rating in a research report on Monday, July 20th. UBS Group lifted their target price on shares of JPMorgan Chase & Co. from $375.00 to $384.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Finally, Deutsche Bank Aktiengesellschaft raised shares of JPMorgan Chase & Co. from a “hold” rating to a “buy” rating and set a $375.00 price target on the stock in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eleven have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $358.67.

View Our Latest Stock Report on JPM

JPMorgan Chase & Co. Stock Performance Shares of JPMorgan Chase & Co. stock opened at $352.18 on Friday. The company has a debt-to-equity ratio of 1.30, a quick ratio of 0.86 and a current ratio of 0.85. JPMorgan Chase & Co. has a 1 year low of $279.10 and a 1 year high of $359.30. The firm’s 50-day simple moving average is $328.81 and its 200-day simple moving average is $311.88. The firm has a market cap of $943.68 billion, a PE ratio of 15.09, a price-to-earnings-growth ratio of 1.44 and a beta of 0.99.

JPMorgan Chase & Co. (NYSE:JPM – Get Free Report) last released its quarterly earnings data on Tuesday, July 14th. The financial services provider reported $6.14 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.55. The firm had revenue of $58.02 billion during the quarter, compared to the consensus estimate of $50.72 billion. JPMorgan Chase & Co. had a net margin of 21.86% and a return on equity of 18.23%. The firm’s revenue was up 27.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.96 earnings per share. Equities analysts forecast that JPMorgan Chase & Co. will post 24.27 earnings per share for the current fiscal year.

JPMorgan Chase & Co. Dividend Announcement The business also recently declared a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Monday, July 6th were issued a $1.50 dividend. The ex-dividend date of this dividend was Monday, July 6th. This represents a $6.00 annualized dividend and a dividend yield of 1.7%. JPMorgan Chase & Co.’s dividend payout ratio is currently 25.71%.

Insider Buying and Selling at JPMorgan Chase & Co. In other news, CFO Jeremy Barnum sold 3,022 shares of JPMorgan Chase & Co. stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $309.41, for a total transaction of $935,037.02. Following the transaction, the chief financial officer owned 32,438 shares in the company, valued at approximately $10,036,641.58. The trade was a 8.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Stacey Friedman sold 5,468 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $300.27, for a total value of $1,641,876.36. Following the completion of the transaction, the general counsel owned 46,428 shares in the company, valued at $13,940,935.56. This represents a 10.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 18,876 shares of company stock valued at $5,907,051. Corporate insiders own 0.41% of the company’s stock.

More JPMorgan Chase & Co. News Here are the key news stories impacting JPMorgan Chase & Co. this week:

Positive Sentiment: New ETF expands fee-generating asset-management platform: J.P. Morgan Asset Management launched the actively managed JPMorgan U.S. Large Cap Value Plus ETF (JLVP), its first ETF using a long/short extension strategy. The product gives retail investors access to the firm’s value-investing research and could support long-term asset-gathering and fee revenue. J.P. Morgan Asset Management Launches JLVP Positive Sentiment: Analyst earnings outlook improved: Erste Group Bank raised its FY2026 EPS forecast for JPMorgan to $24.90 from $22.76, above the $24.27 consensus estimate. The revision reinforces confidence in JPMorgan’s diversified revenue base and earnings momentum. Erste Group raises JPMorgan earnings estimate Positive Sentiment: Higher-for-longer rates may support net interest income: Analysis of the Federal Reserve’s hawkish pause highlighted JPMorgan’s rising 2026 net-interest-income outlook, strong capital position and diversified businesses as potential advantages if rates remain elevated. Fed’s hawkish pause analysis Neutral Sentiment: JPMorgan is leading the arranger group for CoreWeave’s $2.6 billion first-lien term loan. The transaction should generate underwriting fees, but the wider-than-initially marketed pricing reflects elevated borrower risk and does not materially change JPMorgan’s investment case. CoreWeave completes term loan Neutral Sentiment: A correction lowered previously reported cash distributions for two Canadian-listed JPMorgan ETFs. The change affects fund investors more directly than JPMorgan’s corporate earnings. JPMorgan ETF distribution correction Negative Sentiment: Dimon’s warnings that investors should prepare for volatility and avoid certain low-yield investments may reinforce concerns that markets and bank valuations face macroeconomic risks. Jamie Dimon investor warning Negative Sentiment: Coverage of JPMorgan’s involvement in FIFA’s plans to raise billions has triggered another football-related backlash, creating a reputational risk even though the direct financial impact is unclear. JPMorgan and FIFA controversy JPMorgan Chase & Co. Company Profile (Free Report)

JPMorgan Chase & Co (NYSE: JPM) is a diversified global financial services firm headquartered in New York City. The company provides a wide range of banking and financial products and services to consumers, small businesses, corporations, governments and institutional investors worldwide. Its operations span retail banking, commercial lending, investment banking, asset management, payments and card services, and treasury and securities services.

The firm’s principal business activities are organized across several core lines: Consumer & Community Banking, which offers deposit accounts, mortgages, auto loans, credit cards and branch and digital banking under the Chase brand; Corporate & Investment Banking, which provides capital markets, advisory, underwriting, trading and risk management services; Commercial Banking, delivering lending, treasury and capital solutions to middle-market and corporate clients; and Asset & Wealth Management, which offers investment management, private banking and retirement services to institutions and high-net-worth individuals.

Further Reading Five stocks we like better than JPMorgan Chase & Co. Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case Apple’s Record Quarter Could Not Outrun Its Guidance Problem McKesson’s Compounding Keeps Adding Up Want to see what other hedge funds are holding JPM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for JPMorgan Chase & Co. (NYSE:JPM – Free Report).

Receive News & Ratings for JPMorgan Chase & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JPMorgan Chase & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Posted by Defense World Staff on Aug 1st, 2026

Bank of America Corp DE decreased its holdings in Intel Corporation (NASDAQ:INTC – Free Report) by 7.3% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,381,848 shares of the chip maker’s stock after selling 1,841,195 shares during the quarter. Bank of America Corp DE owned 0.47% of Intel worth $1,031,841,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of INTC. iA Global Asset Management Inc. boosted its holdings in Intel by 17.0% in the 4th quarter. iA Global Asset Management Inc. now owns 593,043 shares of the chip maker’s stock worth $21,883,000 after buying an additional 86,189 shares during the period. Whalerock Point Partners LLC bought a new stake in Intel during the 4th quarter valued at $205,000. Heritage Investment Group Inc. purchased a new stake in shares of Intel during the fourth quarter worth $219,000. Dixon Mitchell Investment Counsel Inc. purchased a new stake in shares of Intel during the fourth quarter worth $185,000. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Intel by 5.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 255,261 shares of the chip maker’s stock worth $9,419,000 after acquiring an additional 13,858 shares during the period. Institutional investors own 64.53% of the company’s stock.

Analyst Ratings Changes Several equities analysts have recently weighed in on INTC shares. Citigroup upgraded Intel from a “positive” rating to a “buy” rating in a research report on Thursday, July 23rd. TD Cowen raised their target price on Intel from $75.00 to $115.00 and gave the stock a “hold” rating in a research note on Monday, July 13th. Bank of America restated a “buy” rating and issued a $160.00 target price on shares of Intel in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intel in a report on Tuesday, July 21st. Finally, BTIG Research upgraded Intel from a “neutral” rating to a “buy” rating in a research report on Thursday, June 11th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, twenty-nine have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $107.93.

Get Our Latest Stock Report on Intel

Trending Headlines about Intel Here are the key news stories impacting Intel this week:

Positive Sentiment: Potential Apple supply opportunity: Melius suggested Apple could use Intel alongside its primary processor supplier to reduce manufacturing risk. A win with Apple would strengthen Intel’s foundry ambitions and provide a high-profile customer opportunity. Intel Stock Rises as Analyst Sees Apple Supply Opportunity Positive Sentiment: AI spending and sector inflows are lifting sentiment: Strong Microsoft and Amazon results renewed confidence in cloud and AI infrastructure spending, helping semiconductor stocks recover. Semiconductor ETFs also attracted substantial new cash this week, creating broader buying support for chip names including Intel. Semiconductor ETFs Draw Cash This Week as Chip Stocks Rally Positive Sentiment: Bullish commentary and earnings momentum: Jim Cramer argued that Intel belongs near $110 and said forced selling by the Situational Awareness hedge fund exaggerated the post-earnings decline. Intel’s latest quarterly results also exceeded consensus estimates, with revenue rising more than 25% year over year, while investors continue to focus on its restructuring and improving data-center business. Jim Cramer Says INTC Stock Belongs at $110 Neutral Sentiment: Technical recovery remains uncertain: Intel has stabilized after a sharp earnings-related selloff, but technical resistance is identified around $98–$102. The stock’s elevated volatility means the rebound could remain susceptible to further reversals. Intel Stock Reclaims Momentum Near Key Resistance Negative Sentiment: TSMC is challenging Intel’s packaging advantage: Taiwan Semiconductor is reportedly developing technology similar to Intel’s EMIB advanced packaging, potentially weakening a key differentiator as Nvidia evaluates packaging options. This raises competitive concerns for Intel’s foundry and AI strategy. TSMC Developing Advanced Chip Packaging Technology Negative Sentiment: Expectations and valuation risk remain high: After the rebound, investors are demanding evidence that Intel can sustain AI-related growth and execute its costly turnaround. Analysts remain divided, and the company’s negative net margin and ongoing restructuring add to concerns about near-term profitability. Intel Stock Down 1.0% INTC opened at $90.20 on Friday. The business’s fifty day simple moving average is $113.14 and its 200 day simple moving average is $79.70. Intel Corporation has a 52 week low of $18.97 and a 52 week high of $142.35. The company has a quick ratio of 1.25, a current ratio of 1.60 and a debt-to-equity ratio of 0.47. The stock has a market cap of $454.97 billion, a PE ratio of -42.75 and a beta of 2.18.

Intel (NASDAQ:INTC – Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The chip maker reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.21. Intel had a positive return on equity of 2.62% and a negative net margin of 19.79%.The firm had revenue of $16.13 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the company posted ($0.10) earnings per share. The company’s revenue was up 25.2% compared to the same quarter last year. Intel has set its Q3 2026 guidance at 0.380-0.380 EPS. As a group, research analysts expect that Intel Corporation will post 1.01 earnings per share for the current fiscal year.

Intel Profile (Free Report)

Intel Corporation, founded in 1968 by Robert Noyce and Gordon E. Moore and headquartered in Santa Clara, California, is a leading global designer and manufacturer of semiconductor products. The company is historically notable for introducing the first commercial microprocessor and for driving the x86 architecture that underpins many personal computers and servers. Intel’s core business spans the design, fabrication and marketing of processors, chipsets and related components for a wide range of computing applications.

Intel’s product portfolio includes client and mobile processors marketed under brands such as Intel Core and Pentium, as well as high-performance Xeon processors for data centers and cloud infrastructure.

Featured Stories Five stocks we like better than Intel Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case Apple’s Record Quarter Could Not Outrun Its Guidance Problem McKesson’s Compounding Keeps Adding Up Want to see what other hedge funds are holding INTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intel Corporation (NASDAQ:INTC – Free Report).

Receive News & Ratings for Intel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intel and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of America Corp DE Acquires 8,461 Shares of iShares Russell Mid-Cap Growth ETF $IWP

NEXT HEADLINE »Vanguard Real Estate ETF $VNQ Shares Sold by Bank of America Corp DE

Posted by Defense World Staff on Aug 1st, 2026

Bank of America Corp DE raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,189,584 shares of the biopharmaceutical company’s stock after buying an additional 32,158 shares during the quarter. Bank of America Corp DE owned approximately 1.13% of Regeneron Pharmaceuticals worth $919,120,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Norges Bank purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $1,012,296,000. Price T Rowe Associates Inc. MD raised its position in Regeneron Pharmaceuticals by 142.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares during the period. Nuveen LLC raised its position in Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after purchasing an additional 835,240 shares during the period. Wellington Management Group LLP lifted its stake in shares of Regeneron Pharmaceuticals by 8,620.0% during the fourth quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company’s stock worth $512,881,000 after purchasing an additional 656,845 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 528.7% during the third quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after purchasing an additional 606,612 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Regeneron Pharmaceuticals News Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Q2 results substantially exceeded expectations. Regeneron reported non-GAAP EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion versus estimates of $3.82 billion. Revenue rose 16.7% year over year. Growth was led by record Dupixent sales, which increased 38%, and U.S. EYLEA HD sales, which jumped 52% to $596 million. Regeneron Q2 2026 Results Positive Sentiment: Several analysts raised their price targets after the report. Cantor Fitzgerald lifted its target to $795 and maintained an overweight rating, while Truist raised its target to $772 and reiterated buy. These targets imply additional upside based on the referenced current price. Analyst Price Target Updates Neutral Sentiment: Analyst sentiment remains mixed. Morgan Stanley raised its target to $758 and RBC to $737, but both maintained equal-weight or sector-perform ratings. Wells Fargo also raised its target to $750 while keeping an equal-weight rating, suggesting limited conviction despite the earnings beat. Analyst Price Target Updates Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable August 31 to shareholders of record August 18. The approximately 0.5% yield is modest and is unlikely to be a major stock catalyst. Negative Sentiment: Multiple law firms publicized a securities class action against Regeneron and its executives. The litigation alleges investors were misled about the protocol and prospects of the Phase 3 fianlimab-Libtayo melanoma trial, which ultimately failed and was associated with an approximately $11 billion market-cap loss. The September 14, 2026 lead-plaintiff deadline and continuing legal notices could pressure sentiment and create potential financial and reputational risks. Regeneron Securities Class Action Regeneron Pharmaceuticals Stock Up 3.3% REGN stock opened at $762.63 on Friday. The company has a quick ratio of 2.96, a current ratio of 4.29 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $821.11. The firm’s 50-day simple moving average is $643.13 and its 200 day simple moving average is $711.70. The stock has a market cap of $80.63 billion, a PE ratio of 18.85, a price-to-earnings-growth ratio of 29.50 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter in the previous year, the business earned $12.81 EPS. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 2.06 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be issued a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Wall Street Analysts Forecast Growth Several research firms recently issued reports on REGN. Canaccord Genuity Group dropped their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Truist Financial upped their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research report on Friday. Leerink Partners restated a “market perform” rating and set a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $794.83.

Read Our Latest Analysis on REGN

Insider Activity In other news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Company Profile (Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Further Reading Five stocks we like better than Regeneron Pharmaceuticals Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case Apple’s Record Quarter Could Not Outrun Its Guidance Problem McKesson’s Compounding Keeps Adding Up Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of America Corp DE Acquires 392,210 Shares of Southern Company (The) $SO

NEXT HEADLINE »Bank of America Corp DE Sells 823,167 Shares of Altria Group, Inc. $MO

Posted by Defense World Staff on Aug 1st, 2026

Axiom Investment Management LLC acquired a new position in shares of RTX Corporation (NYSE:RTX – Free Report) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 8,568 shares of the company’s stock, valued at approximately $1,653,000. RTX accounts for about 1.3% of Axiom Investment Management LLC’s portfolio, making the stock its 19th largest position.

Several other hedge funds have also modified their holdings of RTX. Navalign LLC purchased a new stake in RTX during the fourth quarter valued at about $25,000. Commonwealth Retirement Investments LLC purchased a new stake in RTX during the fourth quarter worth approximately $26,000. Core Wealth Advisors LLC acquired a new stake in shares of RTX in the fourth quarter worth $31,000. 1 North Wealth Services LLC increased its position in shares of RTX by 456.7% in the fourth quarter. 1 North Wealth Services LLC now owns 167 shares of the company’s stock worth $31,000 after acquiring an additional 137 shares in the last quarter. Finally, Evergreen Advisors LLC purchased a new stake in RTX during the 1st quarter worth $31,000. 86.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes RTX has been the topic of several research reports. Weiss Ratings raised RTX from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 24th. Robert W. Baird set a $240.00 target price on RTX in a research note on Friday, July 24th. Wells Fargo & Company raised their target price on RTX from $200.00 to $230.00 and gave the company an “equal weight” rating in a report on Friday, July 24th. Susquehanna boosted their price target on RTX from $235.00 to $245.00 and gave the stock a “positive” rating in a research report on Friday, July 24th. Finally, UBS Group increased their price objective on shares of RTX from $198.00 to $215.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $226.94.

Read Our Latest Report on RTX

RTX Stock Up 0.6% Shares of RTX stock opened at $215.58 on Friday. The stock has a market capitalization of $290.55 billion, a price-to-earnings ratio of 37.95, a PEG ratio of 2.55 and a beta of 0.30. RTX Corporation has a twelve month low of $150.61 and a twelve month high of $221.34. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 0.47. The business’s 50 day simple moving average is $191.15 and its 200-day simple moving average is $193.19.

RTX (NYSE:RTX – Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The company reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.66 by $0.23. RTX had a return on equity of 13.99% and a net margin of 8.28%.The firm had revenue of $24.71 billion during the quarter, compared to the consensus estimate of $22.89 billion. During the same period in the prior year, the business earned $1.56 EPS. The firm’s revenue was up 14.5% on a year-over-year basis. RTX has set its FY 2026 guidance at 7.100-7.250 EPS. Equities research analysts forecast that RTX Corporation will post 7.21 earnings per share for the current year.

RTX Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Friday, August 14th will be issued a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, August 14th. RTX’s payout ratio is 51.41%.

Trending Headlines about RTX Here are the key news stories impacting RTX this week:

Positive Sentiment: Pratt & Whitney, RTX’s engine business, received a nearly $1.3 billion undefinitized contract for F135 engine spare parts. The award supports sustainment of engines powering all three F-35 Lightning II variants, strengthening RTX’s defense backlog and long-term revenue visibility. RTX’s Pratt & Whitney awarded $1.3 billion F135 sustainment contract Positive Sentiment: Investor sentiment remains supported by RTX’s latest earnings beat: quarterly revenue rose 14.5% year over year to $24.71 billion, while EPS of $1.89 exceeded consensus by $0.23. Management also raised its full-year 2026 outlook, with guidance of $7.10-$7.25 in EPS, citing a record $289 billion backlog across commercial aftermarket and defense programs. How RTX’s Q2 Beat, Raised Outlook and Record Backlog Will Impact RTX Investors Positive Sentiment: Analyst support has improved after the earnings report, with Morgan Stanley raising its RTX price target. RTX is also being highlighted among industrial stocks positioned to benefit from resilient manufacturing, defense demand and infrastructure investment. Morgan Stanley raises RTX stock price target after earnings Neutral Sentiment: A comparison of RTX with Redwire frames RTX as the more established company, benefiting from scale, execution and a substantial backlog, while Redwire offers potentially faster sales and earnings growth. The analysis underscores RTX’s steadier profile but also suggests investors should weigh its higher valuation against its growth prospects. RTX vs. Redwire: Which Aerospace & Defense Stock Offers More Upside? Negative Sentiment: Reports of insider selling briefly pressured RTX shares, highlighting profit-taking risk after a strong rally toward the stock’s 12-month high. RTX’s valuation—about 38 times earnings—also leaves the stock more sensitive to any disappointment in execution or guidance. RTX shares down following insider selling Insiders Place Their Bets In other news, insider Troy D. Brunk sold 8,557 shares of the stock in a transaction that occurred on Friday, July 24th. The shares were sold at an average price of $210.29, for a total value of $1,799,451.53. Following the completion of the transaction, the insider directly owned 8,809 shares in the company, valued at $1,852,444.61. This trade represents a 49.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Kevin G. Dasilva sold 4,760 shares of the stock in a transaction on Friday, July 24th. The shares were sold at an average price of $213.62, for a total value of $1,016,831.20. Following the transaction, the vice president directly owned 22,349 shares of the company’s stock, valued at approximately $4,774,193.38. The trade was a 17.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 15,567 shares of company stock valued at $3,304,375 in the last quarter. 0.10% of the stock is currently owned by insiders.

RTX Company Profile (Free Report)

RTX (NYSE: RTX) is a U.S.-based aerospace and defense company that designs, manufactures and services advanced systems for commercial, military and governmental customers worldwide. The company was created through the 2020 combination of Raytheon Company and United Technologies Corporation and later adopted the RTX name, positioning itself as a diversified provider across the aerospace and defense value chain.

RTX’s operations span a broad set of capabilities. Its commercial aerospace businesses include Pratt & Whitney aircraft engines and Collins Aerospace systems, which supply propulsion, avionics, aerostructures, interiors and integrated aircraft systems.

Read More Five stocks we like better than RTX Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case Apple’s Record Quarter Could Not Outrun Its Guidance Problem McKesson’s Compounding Keeps Adding Up Want to see what other hedge funds are holding RTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RTX Corporation (NYSE:RTX – Free Report).

Receive News & Ratings for RTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTX and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEMerck & Co., Inc. $MRK Position Boosted by Arete Wealth Advisors LLC

NEXT HEADLINE »Amundi Has $143.06 Million Position in Tetra Tech, Inc. $TTEK

Axiom Investment Management LLC acquired a new position in shares of General Dynamics Corporation (NYSE:GD – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,680 shares of the aerospace company’s stock, valued at approximately $1,263,000. General Dynamics makes up about 1.0% of Axiom Investment Management LLC’s investment portfolio, making the stock its 29th biggest position.

A number of other institutional investors have also added to or reduced their stakes in GD. AQR Capital Management LLC boosted its stake in General Dynamics by 118.3% during the 3rd quarter. AQR Capital Management LLC now owns 1,663,847 shares of the aerospace company’s stock valued at $567,372,000 after purchasing an additional 901,679 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of General Dynamics by 35.0% in the third quarter. Northern Trust Corp now owns 3,332,917 shares of the aerospace company’s stock valued at $1,136,525,000 after purchasing an additional 863,392 shares in the last quarter. Balyasny Asset Management L.P. boosted its position in shares of General Dynamics by 831.1% during the third quarter. Balyasny Asset Management L.P. now owns 737,259 shares of the aerospace company’s stock valued at $251,405,000 after buying an additional 658,081 shares during the last quarter. Vanguard Group Inc. grew its holdings in General Dynamics by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 24,767,330 shares of the aerospace company’s stock worth $8,338,169,000 after buying an additional 528,769 shares in the last quarter. Finally, Corient Private Wealth LLC lifted its position in shares of General Dynamics by 613.0% during the 4th quarter. Corient Private Wealth LLC now owns 613,732 shares of the aerospace company’s stock worth $206,619,000 after buying an additional 527,651 shares in the last quarter. 86.14% of the stock is owned by institutional investors and hedge funds.

More General Dynamics News Here are the key news stories impacting General Dynamics this week:

Positive Sentiment: Strong Q2 results: General Dynamics reported adjusted earnings of $4.24 per share and revenue of $14.09 billion, exceeding estimates of $3.96 and $13.52 billion, respectively. Revenue increased 8.1% year over year, while management highlighted broad-based strength, record backlog and solid cash generation. General Dynamics Corporation Q2 2026 Earnings Call Summary Positive Sentiment: Largest catalyst is the submarine award: General Dynamics Electric Boat received $29.5 billion for five Columbia-class submarines and $42.1 billion for nine Virginia-class submarines, plus infrastructure support. The $76.6 billion award strengthens long-term visibility and backlog, although the contract value will be recognized over many years. General Dynamics Electric Boat Submarine Award Positive Sentiment: Analyst targets moved higher: Morgan Stanley raised its target to $465 and maintained an overweight rating, Susquehanna lifted its target to $455 with a positive rating, and BNP Paribas Exane raised its target to $430 with an outperform rating. These revisions reflect confidence in GD’s backlog and defense demand. Positive Sentiment: Growth profile remains attractive: Zacks cited General Dynamics’ earnings growth, improving business momentum and favorable growth characteristics, while the company maintained fiscal 2026 earnings guidance of approximately $16.80–$16.90 per share. Why General Dynamics Is a Strong Growth Stock Neutral Sentiment: Valuation is increasingly debated: Some research indicates the shares could remain below estimated intrinsic value, while other analysts argue that the strong defense outlook is already reflected in the stock’s elevated valuation after its substantial multiyear gains. Negative Sentiment: Risks remain: Analysts have cited supply-chain and margin pressures, limited visibility into future U.S. defense spending and potential execution challenges associated with the large submarine program. Several reports maintain neutral or downgrade views despite the strong fundamentals. Insider Activity at General Dynamics In other General Dynamics news, EVP Mark Lagrand Burns sold 36,480 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $345.29, for a total transaction of $12,596,179.20. Following the transaction, the executive vice president directly owned 38,975 shares of the company’s stock, valued at approximately $13,457,677.75. The trade was a 48.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark Malcolm sold 5,480 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $365.00, for a total value of $2,000,200.00. Following the completion of the transaction, the director owned 10,643 shares of the company’s stock, valued at approximately $3,884,695. The trade was a 33.99% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 78,190 shares of company stock worth $27,041,022 over the last three months. Insiders own 1.40% of the company’s stock.

Wall Street Analyst Weigh In Several brokerages have commented on GD. TD Cowen lifted their price objective on shares of General Dynamics from $390.00 to $420.00 and gave the stock a “buy” rating in a research report on Thursday. Susquehanna upped their price objective on General Dynamics from $420.00 to $455.00 and gave the company a “positive” rating in a research note on Thursday. Citigroup increased their price objective on General Dynamics from $364.00 to $404.00 and gave the company a “neutral” rating in a report on Thursday. Bank of America boosted their target price on General Dynamics from $400.00 to $415.00 and gave the company a “buy” rating in a research note on Monday, July 6th. Finally, The Goldman Sachs Group dropped their price target on General Dynamics from $327.00 to $313.00 and set a “sell” rating on the stock in a research report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, General Dynamics presently has an average rating of “Moderate Buy” and an average target price of $406.32.

Check Out Our Latest Stock Report on GD

General Dynamics Price Performance Shares of General Dynamics stock opened at $384.53 on Friday. The firm has a market capitalization of $104.04 billion, a PE ratio of 23.46, a price-to-earnings-growth ratio of 2.26 and a beta of 0.34. The company has a current ratio of 1.44, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. General Dynamics Corporation has a 12 month low of $306.03 and a 12 month high of $400.00. The business’s 50-day moving average price is $360.75 and its 200-day moving average price is $352.93.

General Dynamics (NYSE:GD – Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The aerospace company reported $4.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.96 by $0.28. General Dynamics had a net margin of 8.18% and a return on equity of 17.43%. The business had revenue of $14.09 billion during the quarter, compared to analyst estimates of $13.52 billion. During the same period in the prior year, the business posted $3.74 earnings per share. The company’s revenue was up 8.1% on a year-over-year basis. General Dynamics has set its FY 2026 guidance at 16.800-16.900 EPS. Sell-side analysts forecast that General Dynamics Corporation will post 16.97 EPS for the current fiscal year.

General Dynamics Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 7th. Stockholders of record on Thursday, July 2nd will be paid a dividend of $1.59 per share. This represents a $6.36 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Thursday, July 2nd. General Dynamics’s dividend payout ratio is 38.80%.

General Dynamics Profile (Free Report)

General Dynamics is a major American aerospace and defense contractor that designs, manufactures and supports a broad range of products and services for government and commercial customers worldwide. Headquartered in the United States (Reston, Virginia), the company supplies platforms and systems used by armed forces, civil authorities and private operators across multiple domains including air, land, sea and cyber.

Its principal activities span several operating businesses: a business aviation unit that develops and supports Gulfstream business jets; land systems that produce armored combat vehicles and related logistics and sustainment services; marine systems that design and construct submarines and surface ships for navies; and mission systems and information technology operations that provide command-and-control, communications, cybersecurity and systems-integration services.

See Also Five stocks we like better than General Dynamics Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case Apple’s Record Quarter Could Not Outrun Its Guidance Problem McKesson’s Compounding Keeps Adding Up Want to see what other hedge funds are holding GD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for General Dynamics Corporation (NYSE:GD – Free Report).

Receive News & Ratings for General Dynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for General Dynamics and related companies with MarketBeat.com's FREE daily email newsletter.

Posted by Defense World Staff on Aug 1st, 2026

Arete Wealth Advisors LLC lowered its position in Lam Research Corporation (NASDAQ:LRCX – Free Report) by 43.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,174 shares of the semiconductor company’s stock after selling 10,317 shares during the quarter. Arete Wealth Advisors LLC’s holdings in Lam Research were worth $2,813,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Cedar Mountain Advisors LLC increased its stake in Lam Research by 242.9% in the first quarter. Cedar Mountain Advisors LLC now owns 120 shares of the semiconductor company’s stock valued at $26,000 after acquiring an additional 85 shares during the period. Vermillion Wealth Management Inc. bought a new position in shares of Lam Research during the 1st quarter worth approximately $26,000. Bayban acquired a new stake in Lam Research in the 4th quarter valued at $26,000. Mcguire Capital Advisors Inc. acquired a new stake in Lam Research in the 4th quarter valued at $27,000. Finally, Core Wealth Advisors LLC bought a new stake in Lam Research in the fourth quarter valued at $29,000. Institutional investors and hedge funds own 84.61% of the company’s stock.

Lam Research News Roundup Here are the key news stories impacting Lam Research this week:

Positive Sentiment: Strong fiscal fourth-quarter results and outlook: Lam reported record revenue of $6.72 billion, up approximately 30% year over year, and adjusted EPS of $1.82 versus the $1.69 consensus estimate. Management’s outlook for the next quarter—approximately $8.1 billion in revenue and $2.00–$2.30 in EPS—significantly exceeded expectations. NAND revenue more than doubled sequentially, while customer-support revenue reached another record. LRCX Q4 Earnings Beat on NAND and Customer Support Strength Positive Sentiment: AI and memory demand remain key catalysts: Analysts and investors see Lam benefiting from ongoing AI infrastructure spending, advanced chip production, NAND investment, packaging, and wafer-fabrication demand. Some commentary describes an “extraordinary runway” heading into 2027. This Chip Stock Could Be the Biggest Winner of the AI Memory Boom Positive Sentiment: China memory concerns may be overstated: Mizuho argued that fears of Chinese producer CXMT flooding the DRAM market and pressuring prices are overblown, easing a potential risk to semiconductor-equipment demand. Tech specialist explains why China memory fears are overblown Neutral Sentiment: Analyst views remain broadly constructive but targets are mixed: Needham reaffirmed a Buy rating and $390 target, while Morgan Stanley lowered its target from $404 to $367 and B. Riley reduced its target from $385 to $350, retaining Buy or Overweight ratings. The target cuts suggest expectations are being moderated after the rally, even though analysts still see potential upside. Needham Raises Lam Research EPS Estimates Negative Sentiment: Valuation and insider selling are overhangs: After rising roughly 3.9 times over five years and trading at a high earnings multiple, LRCX may be vulnerable to profit-taking. Reported insider activity shows sales rather than purchases over the past six months, reinforcing caution around current valuation. Has Lam Research Fallen Far Enough to Look Like a Bargain? Lam Research Stock Down 1.5% Shares of NASDAQ:LRCX opened at $293.15 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.63 and a quick ratio of 1.77. The stock has a market cap of $366.60 billion, a price-to-earnings ratio of 50.89, a P/E/G ratio of 1.77 and a beta of 1.80. The company has a 50 day moving average of $340.82 and a 200-day moving average of $276.47. Lam Research Corporation has a one year low of $90.93 and a one year high of $438.50.

Lam Research (NASDAQ:LRCX – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The semiconductor company reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.69 by $0.13. Lam Research had a net margin of 31.27% and a return on equity of 67.60%. The business had revenue of $6.72 billion for the quarter, compared to analyst estimates of $6.66 billion. During the same period in the prior year, the business posted $1.33 earnings per share. Lam Research’s revenue was up 30.0% compared to the same quarter last year. Lam Research has set its Q1 2027 guidance at 2.000-2.300 EPS. On average, sell-side analysts forecast that Lam Research Corporation will post 7.92 earnings per share for the current year.

Lam Research Announces Dividend The business also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Wednesday, June 17th were paid a $0.26 dividend. The ex-dividend date of this dividend was Wednesday, June 17th. This represents a $1.04 annualized dividend and a yield of 0.4%. Lam Research’s dividend payout ratio is presently 18.06%.

Analyst Ratings Changes Several equities research analysts have recently commented on the stock. Wall Street Zen downgraded shares of Lam Research from a “buy” rating to a “hold” rating in a research note on Sunday, May 10th. Jefferies Financial Group set a $335.00 price objective on shares of Lam Research and gave the stock a “buy” rating in a report on Thursday. HSBC reiterated a “hold” rating and issued a $333.00 target price on shares of Lam Research in a research note on Monday. New Street Research increased their price target on Lam Research from $235.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, April 27th. Finally, Citigroup restated a “buy” rating and set a $450.00 price target (up from $315.00) on shares of Lam Research in a research report on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-six have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, Lam Research presently has an average rating of “Moderate Buy” and an average target price of $358.47.

View Our Latest Stock Report on LRCX

Insiders Place Their Bets In other Lam Research news, Director Abhijit Y. Talwalkar sold 18,282 shares of the firm’s stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $335.00, for a total transaction of $6,124,470.00. Following the transaction, the director owned 87,142 shares in the company, valued at approximately $29,192,570. This trade represents a 17.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Eric Brandt sold 54,500 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $350.80, for a total transaction of $19,118,600.00. Following the completion of the sale, the director owned 199,205 shares in the company, valued at $69,881,114. This represents a 21.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 80,441 shares of company stock worth $27,614,296. Insiders own 0.31% of the company’s stock.

About Lam Research (Free Report)

Lam Research Corporation (NASDAQ: LRCX) is a global supplier of wafer fabrication equipment and services to the semiconductor industry. Founded in 1980 by David K. Lam and headquartered in Fremont, California, the company develops and manufactures systems used in multiple stages of semiconductor device production, including thin film deposition, plasma etch, wafer cleaning and related process modules and automation.

Lam’s product portfolio covers core process technologies employed by logic and memory manufacturers, with equipment designed to support advanced-node patterning, 3D NAND and other emerging device architectures.

See Also Five stocks we like better than Lam Research Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case Apple’s Record Quarter Could Not Outrun Its Guidance Problem McKesson’s Compounding Keeps Adding Up

Receive News & Ratings for Lam Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lam Research and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAxiom Investment Management LLC Acquires New Holdings in Johnson & Johnson $JNJ

NEXT HEADLINE »Allen Capital Group LLC Invests $2.32 Million in O’Reilly Automotive, Inc. $ORLY

Best Buy is at a critical juncture as the consumer electronics retailer aims to revitalize its performance under incoming CEO Jason Bonfig, who spoke exclusively with CNBC about his strategy for the company.

The company has been struggling with slumping sales over the past few years, which it has attributed to lower consumer confidence, less tech innovation and a slower housing market. In an effort to refresh its products, improve the customer experience and drive more sales, the retailer announced Bonfig will succeed current CEO Corie Barry this fall.

As he prepares to take the helm, Bonfig has said he's focused on four key pillars: advancing Best Buy as a retail and technology company, improving its reach, enhancing the customer experience and focusing on being a human-powered company. Bonfig has also said he's looking into ways to capitalize on the artificial intelligence boom and Best Buy's spot in that next chapter.

This week, Best Buy opened two new stores, one in Jonesboro, Arkansas, and one in Cape Cod, Massachusetts, which Bonfig told CNBC illustrates his strategy as he prioritizes returning the company to long-term and sustainable growth.

"What we're finding is that there are markets that we just can't be in with a traditional size Best Buy store, but they're markets that absolutely make sense for Best Buy from a reach perspective," Bonfig said.

To lean into those markets, the company is opening new small-format stores, ranging from 12,000 to 15,000 square feet, compared to its medium-format stores, which range from 20,000 to 25,000 square feet. Some of its largest stores, including its flagship location in New York City, exceed 40,000 square feet.

The new small stores tap into Bonfig's priority of expanding the company's reach, he said.

"We also know that when we put a store close to a customer, it doesn't just change the customers' behavior in the frequency of the visits of the store … it also changes their behavior digitally as well," Bonfig said.

When Best Buy joins a new, smaller community, he said, the company has found more customers physically go to a store for the first time, but they also use the app and digital channels as well. The Jonesboro store marks Best Buy's return to the town after a tornado destroyed its previous location.

"It's a great example of a vibrant market, a place where customers are interested in our brand, but not a market that could support a 30,000- or 35,000-square-foot store," Bonfig said. "An 18,000-square-foot store allows us to have the best of all of our different categories and meet the needs at that particular location."

The second opening, in Cape Cod, is slightly larger than Best Buy's normal medium-format stores, coming in at 28,000 square feet, but Bonfig said it's another example of finding "the right size store in the right location in the right node."

He added that Best Buy Canada, which can often do things faster than its U.S. counterpart, has been after the small-format store for "an extended period of time" and has seen success with locations as small as 7,000 square feet.

Still, Bonfig emphasized that the small stores are not a replacement for its more typical-format locations.

"It's actually an enhancement of what we're doing today," he said. "But it actually allows us to reach more customers and more markets that we just were not in before."

Trying to turn the pageOver the past five years, Best Buy has seen its stock sink roughly 20% after hitting its peak in late 2021, trading at $138 per share.

For the current fiscal year, Best Buy has said it expects comparable sales in the range of a decline of 1% to an increase of 1%. Though its most recent quarter outperformed Wall Street expectations, it came on the heels of years of declines, like the third fiscal quarter of 2026, when Best Buy reported net income of $140 million, down from $273 million the year prior.

The retailer was also hit by tariffs and is navigating the soaring price of memory chips, which have caused the costs of some consumer electronics to rise.

Bonfig said he attributes Best Buy's recent stagnant performance to a general pull-forward behavior from consumers during Covid that created an unprecedented demand curve that led to a lull. Like home improvement companies, Best Buy saw outsized spending as shoppers were stuck at home and looking to upgrade.

He said Best Buy saw that behavior reset the technology life cycle for a lot of consumers while also forcing vendors to pivot from innovation to production.

"I wouldn't say that Best Buy's lost its momentum," he told CNBC. "I think there's been a very interesting couple years, or maybe more than a couple years, in the market where there was an interesting demand curve where everything was pulled forward."

As he prepares to take the reins of the company, Bonfig said he's focused on improving the customer experience, including upgrading TV selections and working with customers to replace their existing TVs.

Bonfig said he'll define success during his tenure as CEO by the customer response.

He also said the company is leaning into AI for customers and the corporate side of the business, adding that Best Buy is actively investing in new products like Meta's glasses. Best Buy also has an AI tool for customers to use, in addition to partnerships with OpenAI and Google.

"Agentic commerce and commerce through AI platforms is happening today," Bonfig said. "We're seeing traffic there, and we want to make sure that the Best Buy experience is represented."

Still, he added, he expects AI to be an enhancement to the human power behind Best Buy.

And, ultimately, as he looks to step into his new role, Bonfig said he still believes in the core strength of Best Buy despite its recent stagnation.

"Corie had an amazing strategy, and my strategy is built on top of that," Bonfig said. "There is a tremendous amount of momentum."